

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID: ssptanagl626

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

NEWS 1 Web Page URLs for STN Seminar Schedule - N. America
NEWS 2 "Ask CAS" for self-help around the clock
NEWS 3 DEC 18 CA/CAplus pre-1967 chemical substance index entries enhanced with preparation role
NEWS 4 DEC 18 CA/CAplus patent kind codes updated
NEWS 5 DEC 18 MARPAT to CA/CAplus accession number crossover limit increased to 50,000
NEWS 6 DEC 18 MEDLINE updated in preparation for 2007 reload
NEWS 7 DEC 27 CA/CAplus enhanced with more pre-1907 records
NEWS 8 JAN 08 CHEMLIST enhanced with New Zealand Inventory of Chemicals
NEWS 9 JAN 16 CA/CAplus Company Name Thesaurus enhanced and reloaded
NEWS 10 JAN 16 IPC version 2007.01 thesaurus available on STN
NEWS 11 JAN 16 WPIDS/WPINDEX/WPIX enhanced with IPC 8 reclassification data
NEWS 12 JAN 22 CA/CAplus updated with revised CAS roles
NEWS 13 JAN 22 CA/CAplus enhanced with patent applications from India
NEWS 14 JAN 29 PHAR reloaded with new search and display fields
NEWS 15 JAN 29 CAS Registry Number crossover limit increased to 300,000 in multiple databases
NEWS 16 FEB 15 PATDPASPC enhanced with Drug Approval numbers
NEWS 17 FEB 15 RUSSIAPAT enhanced with pre-1994 records
NEWS 18 FEB 23 KOREAPAT enhanced with IPC 8 features and functionality
NEWS 19 FEB 26 MEDLINE reloaded with enhancements
NEWS 20 FEB 26 EMBASE enhanced with Clinical Trial Number field
NEWS 21 FEB 26 TOXCENTER enhanced with reloaded MEDLINE
NEWS 22 FEB 26 IFICDB/IFIPAT/IFIUDB reloaded with enhancements
NEWS 23 FEB 26 CAS Registry Number crossover limit increased from 10,000 to 300,000 in multiple databases
NEWS 24 MAR 15 WPIDS/WPIX enhanced with new FRAGHITSTR display format
NEWS 25 MAR 16 CASREACT coverage extended
NEWS 26 MAR 20 MARPAT now updated daily
NEWS 27 MAR 22 LWPI reloaded

NEWS EXPRESS NOVEMBER 10 CURRENT WINDOWS VERSION IS V8.01c, CURRENT MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP), AND CURRENT DISCOVER FILE IS DATED 25 SEPTEMBER 2006.

NEWS HOURS	STN Operating Hours Plus Help Desk Availability
NEWS LOGIN	Welcome Banner and News Items
NEWS IPC8	For general information regarding STN implementation of IPC 8
NEWS X25	X.25 communication option no longer available

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer Agreement.

10537646

agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

FILE 'HOME' ENTERED AT 07:54:34 ON 28 MAR 2007

=> fil req

COST IN U.S. DOLLARS

SINCE FILE TOTAL

ENTRY SESSTON

FULL ESTIMATED COST

0.21 0.21

FILE 'REGISTRY' ENTERED AT 07:54:40 ON 28 MAR 2007
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2007 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 27 MAR 2007 HIGHEST RN 928296-91-7
DICTIONARY FILE UPDATES: 27 MAR 2007 HIGHEST RN 928296-91-7

New CAS Information Use Policies. enter **HELP USAGETERMS** for details.

TSCA INFORMATION NOW CURRENT THROUGH December 2, 2006

Please note that search-term pricing does apply when conducting SmartSELECT searches.



REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

<http://www.cas.org/ONLINE/UG/reqprops.html>

⇒

Uploading C:\Program Files\Stnexp\Queries\10537646prelim1.str

10537646



chain nodes :

6 7 9 10 11 12

ring nodes :

1 2 3 4 5 8 13 14 15 16 17

chain bonds :

1-6 4-11 5-10 6-7 7-8 7-9 11-12

ring bonds :

1-2 1-5 2-3 3-4 4-5 8-13 8-17 13-14 14-15 15-16 16-17

exact/norm bonds :

1-2 1-5 1-6 2-3 3-4 4-5 4-11 5-10 7-8 7-9 8-13 8-17 11-12 13-14 14-15
15-16 16-17

exact bonds :

6-7

Match level :

1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:CLASS 7:CLASS 8:CLASS 9:CLASS
10:CLASS 11:CLASS 12:CLASS 13:Atom 14:Atom 15:Atom 16:Atom 17:Atom


L1 STRUCTURE UPLOADED

=> d 11

L1 HAS NO ANSWERS

L1 STR

10537646



Structure attributes must be viewed using STN Express query preparation.

=> s 11
SAMPLE SEARCH INITIATED 07:55:23 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED - 12 TO ITERATE

100.0% PROCESSED 12 ITERATIONS 9 ANSWERS
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
BATCH **COMPLETE**
PROJECTED ITERATIONS: 33 TO 447
PROJECTED ANSWERS: 9 TO 360

L2 9 SEA SSS SAM L1

=> s 11 full
FULL SEARCH INITIATED 07:55:28 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 312 TO ITERATE

100.0% PROCESSED 312 ITERATIONS 219 ANSWERS
SEARCH TIME: 00.00.01

L3 219 SEA SSS FUL L1

=> fil hcaplus
COST IN U.S. DOLLARS SINCE FILE TOTAL
FULL ESTIMATED COST ENTRY SESSION
172.10 172.31

FILE 'HCAPLUS' ENTERED AT 07:55:33 ON 28 MAR 2007
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

10537646

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 28 Mar 2007 VOL 146 ISS 14
FILE LAST UPDATED: 27 Mar 2007 (20070327/ED)

New CAS Information Use Policies, enter HELP USAGETERMS for details.


This file contains CAS Registry Numbers for easy and accurate substance identification.

=> s 13
L4 9 L3

=> d ed ibib abs hitstr 1-9

10537646

L4 ANSWER 1 OF 9 HCAPLUS COPYRIGHT 2007 ACS on STN
 ED Entered STN: 13 Nov 2006
 ACCESSION NUMBER: 2006:1190063 HCAPLUS
 DOCUMENT NUMBER: 146:134587
 TITLE: Structure and property-based design of factor Xa inhibitors: Pyrrolidin-2-ones with acyclic alanyl amides as P4 motifs
 AUTHOR(S): Young, Robert J.; Campbell, Matthew; Borthwick, Alan D.; Brown, David; Burns-Kurtis, Cynthia L.; Chan, Chuen; Convery, Maire A.; Crowe, Miriam C.; Dayal, Satish; Diallo, Hawa; Kelly, Henry A.; King, N. Paul; Kleanthous, Savvas; Mason, Andrew M.; Mordaunt, Jackie E.; Patel, Champa; Pateman, Anthony J.; Sengen, Stefan; Shah, Gita P.; Smith, Paul W.; Watson, Nigel S.; Weston, Helen E.; Zhou, Ping
 CORPORATE SOURCE: Medicines Research Centre, GlaxoSmithKline, Stevenage, Hertfordshire, SG1 2NY, UK
 SOURCE: Bioorganic & Medicinal Chemistry Letters (2006), 16(23), 5953-5957
 CODEN: BMCLB9; ISSN: 0960-894X
 PUBLISHER: Elsevier Ltd.
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 OTHER SOURCE(S): CASREACT 146:134587
 GI



AB Nonracemic 1-alaninyl-3-(6-chloro-2-naphthylsulfonylamino)-2-pyrrolidinones such as I are prepared as factor Xa inhibitors for use as anticoagulants: the hydrophobicities, anticoagulant activities in rats, and pharmacokinetics of some of the compds. are determined. For example, I inhibits factor Xa with a Ki value of 1 nM and a value of 2.5 μ M in the prothrombin time assay. 1-Alaninyl-3-(6-chloro-2-naphthylsulfonylamino)-2-pyrrolidinones have poorer pharmacokinetic profiles than the corresponding morpholine-based analogs, with increased plasma clearance and decreased oral bioavailabilities. The structure of I bound to factor Xa is determined by X-ray crystallog.
 IT 478636-52-1
 RL: PAC (Pharmacological activity); PKT (Pharmacokinetics); PRP (Properties); BIOL (Biological study)
 (preparation of pyrrolidinones with acyclic alanyl amides as inhibitors of factor Xa and the anticoagulant activities, hydrophobicities, and pharmacokinetics of selected compds.)
 RN 478636-52-1 HCAPLUS
 CN Morpholine, 4-[(2S)-2-[(3S)-3-[(6-chloro-2-naphthalenyl)sulfonyl]amino]-2-oxo-1-pyrrolidinyl]-1-oxopropyl] - (9CI) (CA INDEX NAME)

L4 ANSWER 2 OF 9 HCAPLUS COPYRIGHT 2007 ACS on STN
 ED Entered STN: 20 Oct 2006
 ACCESSION NUMBER: 2006:1096816 HCAPLUS
 DOCUMENT NUMBER: 145:443880
 TITLE: Odiparcil and a factor Xa inhibitor formulations for treatment of thromboembolic disorders
 INVENTOR(S): Ohlstein, Eliot H.
 PATENT ASSIGNEE(S): Glaxo Group Limited, UK
 SOURCE: PCT Int. Appl. 42pp.
 CODEN: PIXKD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2006110726	A2	20061019	WO 2006-US13448	20060411
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GR, HK, HU, ID, IL, IN, IS, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZH, ZW				
RV: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BU, CF, CG, CI, CH, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, OG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				

PRIORITY APPLN. INFO.: US 2005-669985P P 20050411
 OTHER SOURCE(S): MARPAT 145:443880
 AB The present invention relates to combinations of 4-methyl-2-oxo-2H-1-benzopyran-7-yl-5-thio- β -D-xylopyranoside (odiparcil) and factor Xa inhibitors, methods for producing the combinations, and methods of using the combinations for the treatment and prevention of various thromboembolic disorders in mammals, particularly humans. Thus, 2 parts odiparcil are combined with 1 part by weight rivaroxaban. The combined powders are then optionally milled to desired particle size range. The combination of the 2 drugs is then further combined with a wetting agent, disintegrant and/or filler and compressed into tablets of the following strengths: 50 mg odiparcil/25 mg rivaroxaban/ 100 mg odiparcil/50 mg rivaroxaban/ 200 mg odiparcil/100 mg rivaroxaban/ 250 mg odiparcil/125 mg rivaroxaban.
 IT 478644-12-1 912550-27-7
 RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses); (odiparcil and factor Xa inhibitor formulations for treatment of thromboembolic disorders)
 RN 478644-12-1 HCAPLUS
 CN Morpholine, 4-[(2S)-2-[(3S)-3-[(1E)-2-(5-chloro-2-thienyl)ethenyl]sulfonyl]amino]-2-oxo-1-pyrrolidinyl]-1-oxopropyl] - (9CI) (CA INDEX NAME)

Absolute stereochemistry.
 Double bond geometry as shown.


L4 ANSWER 1 OF 9 HCAPLUS COPYRIGHT 2007 ACS on STN (Continued)

Absolute stereochemistry.



REFERENCE COUNT: 13 THERE ARE 13 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 2 OF 9 HCAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 912550-27-7 HCAPLUS
 CN 2H-1-Benzopyran-2-one, 4-methyl-7-[(5-thio- β -D-xylopyranosyl)oxy]-, mixt. with 4-[(2S)-2-[(3S)-3-[(1E)-2-(5-chloro-2-thienyl)ethenyl]sulfonyl]amino]-2-oxo-1-pyrrolidinyl]-1-oxopropyl)morpholine (9CI) (CA INDEX NAME)

CM 1

CRN 478644-12-1
 CHF C17 H22 Cl N3 O5 S2


Absolute stereochemistry.
 Double bond geometry as shown.



CM 2

CRN 137215-12-4
 CHF C15 H16 O6 S


Absolute stereochemistry.



10537646

L4 ANSWER 3 OF 9 HCPLUS COPYRIGHT 2007 ACS on STN
 ED Entered STN: 09 Oct 2006
 ACCESSION NUMBER: 2006:1048506 HCPLUS
 DOCUMENT NUMBER: 146:38418
 TITLE: Arylsulfonamides: A study of the relationship between activity and conformational preferences for a series of factor Xa inhibitors
 AUTHOR(S): Senger, Stefani; Convery, Maire A.; Chan, Chuen; Watson, Nigel S.
 CORPORATE SOURCE: Medicines Research Centre, GlaxoSmithKline, Stevenage, Hertfordshire, SG1 2NY, UK
 SOURCE: Bioorganic & Medicinal Chemistry Letters (2006), 16(22), 5731-5735
 CODEN: BMCLB; ISSN: 0960-894X
 PUBLISHER: Elsevier Ltd.
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 AB Torsional scans of sulfonamide S-C bonds in small model systems of a series of arylsulfonamide factor Xa inhibitors were performed in order to investigate if conformational effects can help to rationalize the observed SAR. Computational results were in good agreement with the exptl. data indicating that the sulfonamide conformation plays an important role in determining the activity in this particular series of factor Xa inhibitors.
 IT 478644-11-0 478644-13-2 478644-14-3
 478644-69-8 478644-70-1 916585-75-6
 916585-76-7 916585-77-8
 RL: PAC (Pharmacological activity); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (relationship between activity and conformational preferences for a series of factor Xa inhibitors)
 RN 478644-11-0 HCPLUS
 CN 2-Benzofuransulfonamide, 5-chloro-N-[(3S)-1-[(1S)-1-methyl-2-(4-morpholinyl)-2-oxoethyl]-2-oxo-3-pyrrolidinyl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 478644-13-2 HCPLUS
 CN Benzo[b]thiophene-2-sulfonamide, 5-chloro-N-[(3S)-1-[(1S)-1-methyl-2-(4-morpholinyl)-2-oxoethyl]-2-oxo-3-pyrrolidinyl]- (CA INDEX NAME)

Absolute stereochemistry.

RN 478644-14-3 HCPLUS
 CN Benzo[b]thiophene-2-sulfonamide, 5-chloro-N-[(3S)-1-[(1S)-1-methyl-2-(4-morpholinyl)-2-oxoethyl]-2-oxo-3-pyrrolidinyl]- (CA INDEX NAME)


Absolute stereochemistry.

L4 ANSWER 3 OF 9 HCPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 478644-14-3 HCPLUS
 CN Benzo[b]thiophene-2-sulfonamide, 6-chloro-N-[(3S)-1-[(1S)-1-methyl-2-(4-morpholinyl)-2-oxoethyl]-2-oxo-3-pyrrolidinyl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 478644-69-8 HCPLUS
 CN 1H-Indole-2-sulfonamide, 5-chloro-N-[(3S)-1-[(1S)-1-methyl-2-(4-morpholinyl)-2-oxoethyl]-2-oxo-3-pyrrolidinyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 478644-70-1 HCPLUS
 CN 2-Benzothiazolesulfonamide, 6-chloro-N-[(3S)-1-[(1S)-1-methyl-2-(4-morpholinyl)-2-oxoethyl]-2-oxo-3-pyrrolidinyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 916585-75-6 HCPLUS
 CN 2-Benzothiazolesulfonamide, 5-chloro-N-[(3S)-1-[(1S)-1-methyl-2-(4-morpholinyl)-2-oxoethyl]-2-oxo-3-pyrrolidinyl]- (CA INDEX NAME)


L4 ANSWER 3 OF 9 HCPLUS COPYRIGHT 2007 ACS on STN (Continued)

Absolute stereochemistry.




RN 916585-76-7 HCPLUS
 CN 1H-Indole-2-sulfonamide, 6-chloro-N-[(3S)-1-[(1S)-1-methyl-2-(4-morpholinyl)-2-oxoethyl]-2-oxo-3-pyrrolidinyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 916585-77-8 HCPLUS
 CN 2-Benzofuransulfonamide, 6-chloro-N-[(3S)-1-[(1S)-1-methyl-2-(4-morpholinyl)-2-oxoethyl]-2-oxo-3-pyrrolidinyl]- (CA INDEX NAME)


Absolute stereochemistry.



REFERENCE COUNT: 10 THERE ARE 10 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 4 OF 9 HCPLUS COPYRIGHT 2007 ACS on STN


ED Entered STN: 12 Jun 2006
 ACCESSION NUMBER: 2006:548785 HCPLUS
 DOCUMENT NUMBER: 145:188662
 TITLE: Design and synthesis of orally active pyrrolidin-2-one-based factor Xa inhibitors
 AUTHOR(S): Watson, Nigel S.; Brown, David; Campbell, Matthew; Chan, Chuen; Chaudry, Laiq; Convery, Maire A.; Fenwick, Rebecca; Hamblin, J. Nicole; Haslam, Claudine; Kelly, Henry A.; King, N. Paul; Kurtis, Cynthia L.; Leach, Andrew R.; Manchee, Gary R.; Mason, Andrew M.; Mitchell, Charlotte; Patel, Champa; Patel, Vipulkumar K.; Senger, Stefani; Shah, Gita P.; Weston, Helen E.; Whitworth, Caroline; Young, Robert J.
 CORPORATE SOURCE: Medicines Research Centre, GlaxoSmithKline, Stevenage, Hertfordshire, SG1 2NY, UK
 SOURCE: Bioorganic & Medicinal Chemistry Letters (2006), 16(14), 3784-3788
 CODEN: BMCLB; ISSN: 0960-894X
 PUBLISHER: Elsevier B.V.
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 OTHER SOURCE(S): CASREACT 145:188662
 GI



AB A series of novel, non-basic 3-(6-chloronaphth-2-ylsulfonyl)aminopyrrolidin-2-one-based factor Xa (FXa) inhibitors I (R1, R2 = H, Me; R3R4 = piperidinyl, morpholinyl, pyrrolidinyl, etc.), incorporating an alanylamide P4 group, was designed and synthesized. Within this series, I (R1 = H; R2 = Me; R3R4 = morpholinyl) was shown to be a potent, selective FXa inhibitor with good anticoagulant activity. Moreover, this compound possessed highly encouraging rat and dog pharmacokinetic profiles with excellent oral bioavailabilities in both species.

IT 478636-52-1DP, co-crystals with factor Xa
 RL: PRP (Properties); SPN (Synthetic preparation); PREP (Preparation) (crystal structure; preparation of N-carbamoylalkyl (naphthylsulfonylamino)pyrrolidinones as orally active factor Xa inhibitors)
 RN 478636-52-1 HCPLUS
 CN Morpholine, 4-[(2S)-2-[(3S)-3-[(6-chloro-2-naphthalenyl)sulfonyl]amino]-2-oxo-1-pyrrolidinyl]-1-oxopropyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




IT 478636-52-1P 478642-59-0P

RL: PAC (Pharmacological activity); PKT (Pharmacokinetics); RCT (Reactant); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent) (preparation of N-carbamoylalkyl (naphthylsulfonylamino)pyrrolidinones as orally active factor Xa inhibitors)

RN 478636-52-1 HCAPLUS

CN Morpholine, 4-[(2S)-3-[(3S)-1-[(6-chloro-2-naphthalenyl)sulfonyl]amino]-2-oxo-1-pyrrolidinyl]-1-oxopropyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 478642-59-0 HCAPLUS

CN Glycine, N-[(6-chloro-2-naphthalenyl)sulfonyl]-N-[(3S)-1-[(1S)-1-methyl-2-(4-morpholinyl)-2-oxoethyl]-2-oxo-3-pyrrolidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 478641-09-7P 478641-11-1P 478642-41-0P


RL: PAC (Pharmacological activity); PKT (Pharmacokinetics); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation) (preparation of N-carbamoylalkyl (naphthylsulfonylamino)pyrrolidinones as orally active factor Xa inhibitors)

RN 478641-09-7 HCAPLUS

CN Morpholine, 4-[(2S)-2-[(3S)-3-[(6-chloro-2-naphthalenyl)sulfonyl](2-

L4 ANSWER 4 OF 9 HCAPLUS COPYRIGHT 2007 ACS on STN (Continued)
CN Morpholine, 4-[(2S)-2-[(3R)-3-[(6-chloro-2-naphthalenyl)sulfonyl]amino]-2-oxo-1-pyrrolidinyl]-1-oxopropyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 478641-75-7 HCAPLUS

CN Morpholine, 4-[(2R)-2-[(3S)-3-[(6-chloro-2-naphthalenyl)sulfonyl]amino]-2-oxo-1-pyrrolidinyl]-1-oxopropyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 478643-08-2 HCAPLUS

CN Morpholine, 4-[(2R)-2-[(3R)-3-[(6-chloro-2-naphthalenyl)sulfonyl]amino]-2-oxo-1-pyrrolidinyl]-1-oxopropyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 478642-53-4P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent) (preparation of N-carbamoylalkyl (naphthylsulfonylamino)pyrrolidinones as orally active factor Xa inhibitors)


RN 478642-53-4 HCAPLUS

CN Glycine, N-[(6-chloro-2-naphthalenyl)sulfonyl]-N-[(3S)-1-[(1S)-1-methyl-2-(4-morpholinyl)-2-oxoethyl]-2-oxo-3-pyrrolidinyl]-, 1,1-dimethyl-2-ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L4 ANSWER 4 OF 9 HCAPLUS COPYRIGHT 2007 ACS on STN (Continued)
oxobutyl)amino]-2-oxo-1-pyrrolidinyl]-1-oxopropyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 478641-11-1 HCAPLUS

CN Acetamide, 2-[(6-chloro-2-naphthalenyl)sulfonyl][(3S)-1-[(1S)-1-methyl-2-(4-morpholinyl)-2-oxoethyl]-2-oxo-3-pyrrolidinyl]amino]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 478642-41-0 HCAPLUS

CN Morpholine, 4-[(2S)-2-[(3S)-3-[(6-chloro-2-naphthalenyl)sulfonyl]methylamino]-2-oxo-1-pyrrolidinyl]-1-oxopropyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




IT 478637-75-7P 478641-75-7P 478643-08-2P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation) (preparation of N-carbamoylalkyl (naphthylsulfonylamino)pyrrolidinones as orally active factor Xa inhibitors)

RN 478637-75-1 HCAPLUS

L4 ANSWER 4 OF 9 HCAPLUS COPYRIGHT 2007 ACS on STN (Continued)



REFERENCE COUNT:

21 THERE ARE 21 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 5 OF 9 HCPLUS COPYRIGHT 2007 ACS on STN
 ED Entered STN: 27 Jun 2004
 ACCESSION NUMBER: 2004:515501 HCPLUS
 DOCUMENT NUMBER: 141:59669
 TITLE: (E)-2-(5-Chlorothien-2-yl)-N-[(3S)-1-[(1S)-1-methyl-2-morpholin-4-yl-2-oxoethyl]-2-oxopyrrolidin-3-yl]ethenesulfonamide in crystalline form
 INVENTOR(S): Dell'orco, Philip C.; Kelly, Henry Anderson; Shah, Gita Punjabhai; Watson, Nigel Stephen; Young, Robert John
 PATENT ASSIGNEE(S): Glaxo Group Limited, UK
 SOURCE: PCT Int. Appl., 26 pp.
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004052878	A2	20040624	WO 2003-EP13800	20031204
WO 2004052879	A3	20040812		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TH, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2508699	A1	20040624	CA 2003-2508699	20031204
AU 2003293779	A1	20040630	AU 2003-293779	20031204
EP 1567519	A2	20050831	EP 2003-789150	20031204
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
BR 2003017067	A	20051025	BR 2003-17067	20031204
CN 1745079	A	20060308	CN 2003-80109536	20031204
JP 2006510648	T	20060330	JP 2004-558011	20031204
NO 2005003167	A	20050628	NO 2005-3167	20050628
US 2006124049	A1	20060615	US 2005-537645	20051116
PRIORITY APPLN. INFO.:			GB 2002-28533	A 20021206
			WO 2003-EP13800	W 20031204

AB Claimed is the title compound (I) in substantially crystalline form. The X-ray powder diffraction pattern of I in crystalline form is disclosed. Also claimed is the preparation of I in crystalline form by crystallization of I from an organic solution, optionally in the presence of water. Also disclosed is the use of I in crystalline form for the manufacture of a medicament for the treatment of a patient suffering from a condition susceptible to treatment by a Factor Xa inhibitor.

IT 478644-12-1P
 RL: IMF (Industrial manufacture); PRP (Properties); SPN (Synthetic

L4 ANSWER 5 OF 9 HCPLUS COPYRIGHT 2007 ACS on STN (Continued)
 Preparation; USES (Uses)
 (prepn. of (E)-2-(5-chlorothien-2-yl)-N-[(3S)-1-[(1S)-1-methyl-2-morpholin-4-yl-2-oxoethyl]-2-oxopyrrolidin-3-yl]ethenesulfonamide in crystalline form)
 RN 478644-12-1 HCPLUS
 CN Morpholine, 4-[(2S)-2-[(3S)-3-[(1E)-2-(5-chloro-2-thienyl)ethenyl]sulfonyl]amino]-2-oxo-1-pyrrolidinyl]-1-oxopropyl - (9CI) (CA INDEX NAME)

Absolute stereochemistry.
 Double bond geometry as shown.




L4 ANSWER 6 OF 9 HCPLUS COPYRIGHT 2007 ACS on STN
 ED Entered STN: 27 Jun 2004
 ACCESSION NUMBER: 2004:515479 HCPLUS
 DOCUMENT NUMBER: 141:71439
 TITLE: A preparation of pyrrolidinone derivs. useful as inhibitors of thrombin and factor Xa
 INVENTOR(S): Borthwick, Alan David; Chan, Chuen; Kelly, Henry Anderson; Peace, Simon; Senger, Stefan; Shah, Gita Punjabhai; Smith, Stephen Allan; Smith, Steven; Watson, Nigel Stephen; West, Robert Ian; Young, Robert John
 PATENT ASSIGNEE(S): Glaxo Group Limited, UK
 SOURCE: PCT Int. Appl., 128 pp.
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004052851	A1	20040624	WO 2003-EP13799	20031204
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TH, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2003288233	A1	20040630	AU 2003-288233	20031204
EP 1567489	A1	20050831	EP 2003-780129	20031204
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
JP 2006515840	T	20060608	JP 2004-558010	20031204
US 2006166985	A1	20060727	US 2006-537646	20060210
PRIORITY APPLN. INFO.:			GB 2002-28552	A 20021206
OTHER SOURCE(S): MARPAT 141:71439			WO 2003-EP13799	W 20031204

GI

L4 ANSWER 6 OF 9 HCPLUS COPYRIGHT 2007 ACS on STN (Continued)



AB The invention relates to a preparation of pyrrolidinone derivs. of formula I [wherein: R1 is H, Cl-4-alkyl, CH2CO2-Cl-2-alkyl, etc.; R2 and R3 independently represent H, Cl-6alkyl, Cl-3alkyl-CN, or Cl-3alkyl-CO2H, etc.; one of R2 and R3 is H and the other is a substituent other than H; R4 and R5 together with the nitrogen atom to which they are attached form a morpholin ring; R6 represents a group selected from derivs. of halo-substituted thiophenes, pyridines, or benzenes, etc.], useful as inhibitors of thrombin and factor Xa. The obtained pyrrolidinone derivs. were screened for thrombin inhibitory activity and factor Xa inhibitory activity (chromogenic and fluorogenic assays). For instance, pyrrolidinone derivative II (thrombin inhibitory K1<10nM) was prepared from


the obtained intermediates III and IV via amidation (example 2, no yield data).

IT 478644-12-1P 711017-49-1P 711017-61-7P 711017-62-8P 711018-05-2P 711018-06-3P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (intermediate) preparation of pyrrolidinone derivs. useful as inhibitors of thrombin and factor Xa)


RN 478644-12-1 HCPLUS
 CN Morpholine, 4-[(2S)-2-[(3S)-3-[(1E)-2-(5-chloro-2-thienyl)ethenyl]sulfonyl]amino]-2-oxo-1-pyrrolidinyl]-1-oxopropyl - (9CI) (CA INDEX NAME)

Absolute stereochemistry.
 Double bond geometry as shown.




RN 711017-49-1 HCAPLUS
CN Morpholine, 4-[(2S)-2-[(3S)-3-[[{(1E)-2-(5-chloro-2-thienyl)ethylsulfonyl}amino]-2-oxo-1-pyrrolidinyl]-4-methyl-1-oxopentyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 711017-61-7 HCAPLUS
CN Morpholine, 4-[(2S)-2-[(3S)-3-[[{(2-(4-chlorophenyl)-1,3-dioxolan-2-yl)methylsulfonyl}amino]-2-oxo-1-pyrrolidinyl]-3-methyl-1-oxopentyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 711017-62-8 HCAPLUS
CN Morpholine, 4-[(2S)-2-[(3S)-3-[[{(2-(4-chlorophenyl)-1,3-dioxolan-2-yl)methylsulfonyl}amino]-2-oxo-1-pyrrolidinyl]-3-methoxy-1-oxopropyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L4 ANSWER 6 OF 9 HCAPLUS COPYRIGHT 2007 ACS on STN (Continued)
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(prepn. of pyrrolidinone derivs. useful as inhibitors of thrombin and factor Xa)


RN 711018-49-4 HCAPLUS
CN Morpholine, 4-[(2S)-2-[(3S)-3-[[{(2-(5-chloro-2-thienyl)ethylsulfonyl}amino]-2-oxo-1-pyrrolidinyl]-1-oxopropyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 711018-78-9 HCAPLUS
CN 4-Morpholinebutanoic acid, β -[(3S)-3-[[{(2-(5-chloro-2-thienyl)ethylsulfonyl}amino]-2-oxo-1-pyrrolidinyl}- γ -oxo-phenylmethyl ester, (BS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 711018-84-7 HCAPLUS
CN 4-Morpholinebutanoic acid, β -[(3S)-3-[[{(2-(5-chloro-2-thienyl)ethylsulfonyl}amino]-2-oxo-1-pyrrolidinyl}- γ -oxo-, (BS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




IT 711018-50-7P 711018-51-8P 711018-52-9P
711018-53-0P 711018-54-1P 711018-55-2P
711018-56-3P 711018-57-4P 711018-58-5P




RN 711018-05-2 HCAPLUS
CN 4-Morpholinebutanamide, β -[(3S)-3-[[{(2-(5-chloro-2-thienyl)ethylsulfonyl}amino]-2-oxo-1-pyrrolidinyl}-N-(dimethylamino)methylene]- γ -oxo-, [N(E),BS]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 711018-06-3 HCAPLUS
CN 4-Morpholinebutanamide, β -[(3S)-3-[[{(2-(5-chloro-2-thienyl)ethylsulfonyl}amino]-2-oxo-1-pyrrolidinyl}-N-(1-(dimethylamino)ethylidene]- γ -oxo-, (BS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.



IT 711018-49-4P 711018-78-9P 711018-84-7P

711018-59-6P 711018-60-9P 711018-61-0P

711018-62-1P 711018-63-2P 711018-64-3P

711018-65-4P 711018-66-5P 711018-67-6P

711018-69-8P 711018-70-1P 711018-71-2P

711018-72-3P 711018-73-4P 711018-74-5P

711018-75-6P 711018-76-7P 711018-77-8P

711018-79-0P 711018-80-3P 711018-81-4P

711018-82-5P 711018-83-6P 711018-85-8P

711018-86-9P 711018-87-0P 711018-88-1P

711018-89-2P 711018-90-5P 711018-91-6P

711018-92-7P 711018-93-8P 711018-94-9P

711018-95-0P 711018-96-1P 711018-97-2P

711018-98-3P 711018-99-4P 711019-00-0P

711019-01-1P 711019-02-2P 711019-03-3P

711019-04-4P 711019-05-5P 711019-06-6P

711019-07-7P 711019-08-8P 711019-09-9P

711019-10-2P 711019-11-3P 711019-12-4P

711019-13-5P 711019-14-6P 711019-15-7P

711019-16-8P 711019-17-9P 711019-18-0P

711019-19-1P 711019-20-4P 711019-21-5P

711019-22-6P 711019-23-7P 711019-24-8P

711019-25-9P 711019-26-0P 711019-27-1P

711019-28-2P 711019-29-3P 711019-30-6P

711019-31-7P 711019-32-8P 711019-33-9P

711019-34-0P 711019-35-1P 711019-36-2P

711019-37-3P 711019-38-4P 711019-39-5P

711019-40-8P 711019-41-9P 711019-42-0P

711019-43-1P 711019-44-2P 711019-45-3P


711019-46-4P 711019-47-5P 711019-48-6P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of pyrrolidinone derivs. useful as inhibitors of thrombin and factor Xa)

RN 711018-50-7 HCAPLUS

CN Morpholine, 4-[(2S)-2-[(3S)-3-[[{(2-(5-chloro-2-thienyl)ethylsulfonyl}amino]-2-oxo-1-pyrrolidinyl]-4-methyl-1-oxopentyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 711018-51-8 HCAPLUS

CN Morpholine, 4-[(2S)-2-[(3S)-3-[[{(1E)-2-(5-chloro-2-thienyl)-1-propenyl}sulfonyl]amino]-2-oxo-1-pyrrolidinyl]-1-oxopropyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

Double bond geometry as shown.




RN 711018-52-9 HCAPLUS
 CN Morpholine, 4-[(2S)-2-[(3S)-3-[[[(1E)-2-(5-chloro-2-thienyl)-1-propenyl]sulfonyl]amino]-2-oxo-1-pyrrolidinyl]-3-methyl-1-oxobutyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
 Double bond geometry as shown.





RN 711018-53-0 HCAPLUS
 CN Morpholine, 4-[(2S)-2-[(3S)-3-[[[(1E)-2-(5-chloro-2-thienyl)-1-propenyl]sulfonyl]amino]-2-oxo-1-pyrrolidinyl]-1-oxobutyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
 Double bond geometry as shown.




RN 711018-54-1 HCAPLUS
 CN Morpholine, 4-[(2S,3S)-2-[(3S)-3-[[[(2-(5-chloro-2-thienyl)ethyl]sulfonyl]amino]-2-oxo-1-pyrrolidinyl]-3-methyl-1-oxopentyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 711018-59-6 HCAPLUS
 CN Morpholine, 4-[(2S)-2-[(3S)-3-[[[(2-(4-chlorophenyl)ethyl]sulfonyl]amino]-2-oxo-1-pyrrolidinyl]-1-oxopropyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 711018-60-9 HCAPLUS
 CN Morpholine, 4-[(2S)-2-[(3S)-3-[[[(2-(5-chloro-2-thienyl)ethyl]sulfonyl]amino]-2-oxo-1-pyrrolidinyl]-1-oxo-3-phenylpropyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 711018-61-0 HCAPLUS
 CN Morpholine, 4-[(2S)-2-[(3S)-3-[[[(1E)-2-(5-chloro-2-thienyl)-1-propenyl]sulfonyl]amino]-2-oxo-1-pyrrolidinyl]-1-oxo-3-phenylpropyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
 Double bond geometry as shown.


RN 711018-55-2 HCAPLUS
 CN Morpholine, 4-[(2S,3R)-2-[(3S)-3-[[[(1E)-2-(5-chloro-2-thienyl)-1-propenyl]sulfonyl]amino]-2-oxo-1-pyrrolidinyl]-3-methoxy-1-oxobutyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
 Double bond geometry as shown.




RN 711018-56-3 HCAPLUS
 CN Morpholine, 4-[(2S,3S)-2-[(3S)-3-[[[(1E)-2-(5-chloro-2-thienyl)-1-propenyl]sulfonyl]amino]-2-oxo-1-pyrrolidinyl]-3-methyl-1-oxopentyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
 Double bond geometry as shown.




RN 711018-57-4 HCAPLUS
 CN Morpholine, 4-[(2S)-2-[(3S)-3-[[[(2-(5-chloro-2-thienyl)ethyl]sulfonyl]amino]-2-oxo-1-pyrrolidinyl]-1-oxobutyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 711018-58-5 HCAPLUS
 CN Morpholine, 4-[(2S)-2-[(3S)-3-[[[(2-(4-chlorophenyl)ethyl]sulfonyl]amino]-2-oxo-1-pyrrolidinyl]-1-oxobutyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 711018-62-1 HCAPLUS
 CN Morpholine, 4-[(2S)-2-[(3S)-3-[[[(2-(4-chlorophenyl)ethyl) sulfonyl]amino]-2-oxo-1-pyrrolidinyl]-1-oxopropyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 711018-63-2 HCAPLUS
 CN Morpholine, 4-[(2S)-2-[(3S)-3-[[[(2-(4-dichlorophenyl)ethyl) sulfonyl]amino]-2-oxo-1-pyrrolidinyl]-1-oxopropyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 711018-64-3 HCAPLUS
 CN Morpholine, 4-[(2S)-2-[(3S)-3-[[[(2-(4-fluorophenyl)ethyl) sulfonyl]amino]-2-oxo-1-pyrrolidinyl]-1-oxopropyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 711018-65-4 HCPLUS
 CN Morpholine, 4-[(2S)-2-[(3S)-3-[[[2-(4-methylphenyl)ethyl]sulfonyl]amino]-2-oxo-1-pyrrolidinyl]-1-oxopropyl] - (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 711018-66-5 HCPLUS
 CN Morpholine, 4-[(2S)-2-[(3S)-3-[[[(1E)-2-(4-chlorophenyl)-1-propenyl]sulfonyl]amino]-2-oxo-1-pyrrolidinyl]-1-oxopropyl] - (9CI) (CA INDEX NAME)

Absolute stereochemistry.
 Double bond geometry as shown.




RN 711018-67-6 HCPLUS
 CN Morpholine, 4-[(2S,3S)-2-[(3S)-3-[[2-(4-bromophenyl)ethyl]sulfonyl]amino]-

Absolute stereochemistry.
 Double bond geometry as shown.




RN 711018-72-3 HCPLUS
 CN Morpholine, 4-[(2S)-2-[(3S)-3-[[[(1E)-2-(5-chloro-2-thienyl)-1-propenyl]sulfonyl]amino]-2-oxo-1-pyrrolidinyl]-3-methoxy-1-oxopropyl] - (9CI) (CA INDEX NAME)

Absolute stereochemistry.
 Double bond geometry as shown.



RN 711018-73-4 HCPLUS
 CN Morpholine, 4-[(2S)-2-[(3S)-3-[[2-(5-chloro-2-thienyl)ethyl]sulfonyl]amino]-2-oxo-1-pyrrolidinyl]-3-methoxy-1-oxopropyl] - (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 711018-74-5 HCPLUS
 CN Morpholine, 4-[(2S)-2-[(3S)-3-[[2-(4-chlorophenyl)-2,2-difluoroethyl]sulfonyl]amino]-2-oxo-1-pyrrolidinyl]-1-oxopropyl] - (9CI) (CA INDEX NAME)


Absolute stereochemistry.

Absolute stereochemistry.




RN 711018-69-8 HCPLUS
 CN Morpholine, 4-[(2S)-2-[(3S)-3-[[2-(4-bromophenyl)ethyl]sulfonyl]amino]-2-oxo-1-pyrrolidinyl]-1-oxobutyl] - (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 711018-70-1 HCPLUS
 CN Morpholine, 4-[(2S)-2-[(3S)-3-[[2-(4-bromophenyl)ethyl]sulfonyl]amino]-2-oxo-1-pyrrolidinyl]-1-oxopropyl] - (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 711018-71-2 HCPLUS
 CN Morpholine, 4-[(2S)-2-[(3S)-3-[[[(1E)-2-(5-chloro-2-thienyl)-3,3,3-trifluoro-1-propenyl]sulfonyl]amino]-2-oxo-1-pyrrolidinyl]-1-oxopropyl] -




RN 711018-75-6 HCPLUS
 CN Morpholine, 4-[(2S)-2-[(3S)-3-[[[(1Z)-2-(4-chlorophenyl)-2-fluoroethyl]sulfonyl]amino]-2-oxo-1-pyrrolidinyl]-1-oxopropyl] - (9CI) (CA INDEX NAME)

Absolute stereochemistry.
 Double bond geometry as shown.




RN 711018-76-7 HCPLUS
 CN Morpholine, 4-[(2S,3S)-2-[(3S)-3-[[2-(4-chlorophenyl)-2,2-difluoroethyl]sulfonyl]amino]-2-oxo-1-pyrrolidinyl]-3-methyl-1-oxopentyl] - (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 711018-77-8 HCPLUS
 CN Morpholine, 4-[(2S,3S)-2-[(3S)-3-[[[(1Z)-2-(4-chlorophenyl)-2-fluoroethyl]sulfonyl]amino]-2-oxo-1-pyrrolidinyl]-3-methyl-1-oxopentyl] - (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.




RN 711018-79-0 HCAPLUS
CN Morpholine, 4-[(2S,3R)-2-[(3S)-3-[[[2-(5-chloro-2-thienyl)ethyl]sulfonyl]amino]-2-oxo-1-pyrrolidinyl]-3-methoxy-1-oxobutyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 711018-80-3 HCAPLUS
CN Morpholine, 4-[(2S)-2-[(3S)-3-[[[2-(4-chlorophenyl)ethyl]sulfonyl]amino]-2-oxo-1-pyrrolidinyl]-1-oxo-3-(2-thienyl)propyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 711018-81-4 HCAPLUS
CN Morpholine, 4-[(2S)-2-[(3S)-3-[[[2-(5-chloro-2-thienyl)ethyl]sulfonyl]amino]-2-oxo-1-pyrrolidinyl]-3-methyl-1-oxobutyl]- (9CI) (CA INDEX NAME)




RN 711018-86-9 HCAPLUS
CN 4-Morpholinobutanimide, β -[(3S)-3-[[[2-(5-chloro-2-thienyl)ethyl]sulfonyl]amino]-2-oxo-1-pyrrolidinyl]-N,N-dimethyl- γ -oxo-, (BS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 711018-87-0 HCAPLUS
CN Morpholine, 4-[(2S)-2-[(3S)-3-[[[2-(5-chloro-2-thienyl)ethyl]sulfonyl]methylamino]-2-oxo-1-pyrrolidinyl]-1-oxopropyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 711018-88-1 HCAPLUS
CN Acetamide, 2-[[[2-(5-chloro-2-thienyl)ethyl]sulfonyl][(3S)-1-[(1S)-1-methyl-2-(4-morpholinyl)-2-oxoethyl]-2-oxo-3-pyrrolidinyl]amino]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

Absolute stereochemistry.




RN 711018-82-5 HCAPLUS
CN Morpholine, 4-[(2S)-2-[(3S)-3-[[[2-(4-chlorophenyl)ethyl]sulfonyl]amino]-2-oxo-1-pyrrolidinyl]-3-methyl-1-oxobutyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 711018-83-6 HCAPLUS
CN 4-Morpholinobutanoic acid, β -[(3S)-3-[[[1E]-2-(5-chloro-2-thienyl)-1-propenyl]sulfonyl]amino]-2-oxo-1-pyrrolidinyl- γ -oxo-, phenylmethyl ester, (BS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.




RN 711018-85-8 HCAPLUS
CN Morpholine, 4,4'-[(2S)-2-[(3S)-3-[[[2-(5-chloro-2-thienyl)ethyl]sulfonyl]amino]-2-oxo-1-pyrrolidinyl]-1,4-dioxo-1,4-butanediyl]bis- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 711018-89-2 HCAPLUS
CN Glycine, N-[(2-(5-chloro-2-thienyl)ethyl)sulfonyl]-N-[(3S)-1-[(1S)-1-methyl-2-(4-morpholinyl)-2-oxoethyl]-2-oxo-3-pyrrolidinyl]-, ethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 711018-90-5 HCAPLUS
CN Glycine, N-[(2-(5-chloro-2-thienyl)ethyl)sulfonyl]-N-[(3S)-1-[(1S)-1-methyl-2-(4-morpholinyl)-2-oxoethyl]-2-oxo-3-pyrrolidinyl]-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 711018-91-6 HCAPLUS
CN Morpholine, 4-[(2S,3S)-2-[(3S)-3-[[[2-(5-chloro-2-thienyl)ethyl]sulfonyl]methylamino]-2-oxo-1-pyrrolidinyl]-3-methyl-1-oxopentyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 711018-92-7 HCAPLUS
 CN Acetamide, 2-[[2-(5-chloro-2-thienyl)ethyl]sulfonyl][(3S)-1-[(1S,2S)-2-methyl-1-(4-morpholinylcarbonyl)butyl]-2-oxo-3-pyrrolidinylamino]-N-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 711018-93-8 HCAPLUS
 CN Acetamide, 2-[[2-(5-chloro-2-thienyl)ethyl]sulfonyl][(3S)-1-[(1S,2S)-2-methyl-1-(4-morpholinylcarbonyl)butyl]-2-oxo-3-pyrrolidinylamino]-N,N-dimethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 711018-94-9 HCAPLUS
 CN Glycine, N-[(2-(5-chloro-2-thienyl)ethyl)sulfonyl]-N-[(3S)-1-[(1S)-1-methyl-2-(4-morpholinyl)-2-oxoethyl]-2-oxo-3-pyrrolidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 711018-95-0 HCAPLUS
 CN Morpholine, 4-[(2S)-2-[(3S)-3-[[2-(5-chloro-2-pyridinyl)ethyl]sulfonyl]amino]-2-oxo-1-pyrrolidinyl]-1-oxopropyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 711018-96-1 HCAPLUS
 CN Morpholine, 4-[(2S,3S)-2-[(3S)-3-[[2-(5-chloro-2-pyridinyl)ethyl]sulfonyl]amino]-2-oxo-1-pyrrolidinyl]-3-methyl-1-oxopropyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 711018-97-2 HCAPLUS
 CN Morpholine, 4-[(2S)-2-[(3S)-3-[[2-(5-chloro-2-pyridinyl)ethyl]sulfonyl]amino]-2-oxo-1-pyrrolidinyl]-3-ethoxy-1-oxopropyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 711018-98-3 HCAPLUS
 CN Morpholine, 4-[(2S)-2-[(3S)-3-[[2-(5-chloro-2-pyridinyl)ethyl]sulfonyl]amino]-2-oxo-1-pyrrolidinyl]-3-methoxy-1-oxopropyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 711018-99-4 HCAPLUS
 CN Morpholine, 4-[(2S,3S)-2-[(3S)-3-[[2-(4-chlorophenyl)-2-oxethyl]sulfonyl]amino]-2-oxo-1-pyrrolidinyl]-3-methoxy-1-oxopropyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 711019-00-0 HCAPLUS
 CN Morpholine, 4-[(2S)-2-[(3S)-3-[[2-(4-chlorophenyl)-2-oxethyl]sulfonyl]amino]-2-oxo-1-pyrrolidinyl]-3-methoxy-1-oxopropyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 711019-01-1 HCAPLUS
 CN Morpholine, 4-[(2S,3S)-2-[(3S)-3-[[2-(4-chlorophenyl)-2-hydroxyethyl]sulfonyl]amino]-2-oxo-1-pyrrolidinyl]-3-methyl-1-oxopropyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 711019-02-2 HCAPLUS
 CN Morpholine, 4-[(2S)-2-[(3S)-3-[[2-(5-chloro-2-thienyl)propyl]sulfonyl]amino]-2-oxo-1-pyrrolidinyl]-1-oxopropyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 711019-03-3 HCAPLUS
 CN Morpholine, 4-[(2S)-2-[(3S)-3-[[2-(5-chloro-2-thienyl)propyl]sulfonyl]amino]-2-oxo-1-pyrrolidinyl]-1-oxopropyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 711019-04-4 HCPLUS

CN Morpholine, 4-[(2S,3S)-2-[(3S)-3-[[[2-(5-chloro-2-thienyl)propyl]sulfonyl]amino]-2-oxo-1-pyrrolidinyl]-3-methyl-1-oxopropyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 711019-05-5 HCPLUS

CN Morpholine, 4-[(2S)-2-[(3S)-3-[[[2-(5-chloro-2-thienyl)propyl]sulfonyl]amino]-2-oxo-1-pyrrolidinyl]-3-methoxy-1-oxopropyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 711019-06-6 HCPLUS

CN Morpholine, 4-[(2S,3S)-2-[(3S)-3-[[[2-(5-chloro-2-thienyl)propyl]sulfonyl]amino]-2-oxo-1-pyrrolidinyl]-3-ethoxy-1-oxopropyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



L4 ANSWER 6 OF 9 HCPLUS COPYRIGHT 2007 ACS on STN (Continued)

CN Morpholine, 4-[(2S,3S)-2-[(3S)-3-[[[5-chloro-2,3-dihydro-1H-inden-1-yl)methyl]sulfonyl]amino]-2-oxo-1-pyrrolidinyl]-3-methyl-1-oxopropyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 711019-11-3 HCPLUS

CN Morpholine, 4-[(2S)-2-[(3S)-3-[[[(6-chloro-2,3-dihydro-3-benzofuranyl)ethyl]sulfonyl]amino]-2-oxo-1-pyrrolidinyl]-1-oxopropyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 711019-12-4 HCPLUS

CN Morpholine, 4-[(2S)-2-[(3S)-3-[[[(6-chloro-2,3-dihydro-3-benzofuranyl)methyl]sulfonyl]amino]-2-oxo-1-pyrrolidinyl]-3-methoxy-1-oxopropyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 711019-13-5 HCPLUS


CN Morpholine, 4-[(2S)-2-[(3S)-3-[[[(5-chloro-1,3-dihydro-1-isobenzofuranyl)methyl]sulfonyl]amino]-2-oxo-1-pyrrolidinyl]-1-oxopropyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

RN 711019-07-7 HCPLUS

CN Morpholine, 4-[(2S)-2-[(3S)-3-[[[2-(5-chloro-2-thienyl)propyl]sulfonyl]amino]-2-oxo-1-pyrrolidinyl]-3-(3-methyl-1,2,4-oxadiazol-5-yl)-1-oxopropyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 711019-08-9 HCPLUS

CN Morpholine, 4-[(2S)-2-[(3S)-3-[[[(5-chloro-2,3-dihydro-1H-inden-1-yl)methyl]sulfonyl]amino]-2-oxo-1-pyrrolidinyl]-1-oxopropyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.




RN 711019-09-9 HCPLUS

CN Morpholine, 4-[(2S)-2-[(3S)-3-[[[(5-chloro-2,3-dihydro-1H-inden-1-yl)methyl]sulfonyl]amino]-2-oxo-1-pyrrolidinyl]-3-methoxy-1-oxopropyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 711019-10-2 HCPLUS



RN 711019-14-6 HCPLUS

CN Morpholine, 4-[(3S)-3-[[[(2-(5-chloro-2-thienyl)ethyl)sulfonyl]amino]-2-oxo-1-pyrrolidinyl][tetrahydro-2H-pyran-4-yl]acetyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 711019-15-7 HCPLUS

CN Morpholine, 4-[(2S)-2-[(3S)-3-[[[(1R)-5-chloro-2,3-dihydro-1H-inden-1-yl)methyl]sulfonyl]amino]-2-oxo-1-pyrrolidinyl]-3-methoxy-1-oxopropyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 711019-16-8 HCPLUS


CN Morpholine, 4-[(2S)-2-[(3S)-3-[[[(2-(5-chloro-2-thienyl)ethyl)sulfonyl]amino]-2-oxo-1-pyrrolidinyl]phenylacetyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




L4 ANSWER 6 OF 9 HCAPLUS COPYRIGHT 2007 ACS on STN (Continued)
 CN Morpholine, 4-[(2S)-2-[(3S)-3-[[2-(4-chlorophenyl)ethyl]sulfonyl]amino]-2-oxo-1-pyrrolidinyl]-3-(3-methyl-1,2,4-oxadiazol-5-yl)-1-oxopropyl]-(9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 711019-30-6 HCAPLUS
 CN 4-Morpholine, β -[(2S)-2-[(3S)-3-[[2-(5-chloro-2-thienyl)ethyl]sulfonyl]amino]-2-oxo-1-pyrrolidinyl]-N-methyl- γ -oxo-N-(phenylmethyl)-, (β S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 711019-31-7 HCAPLUS
 CN Morpholine, 4-[(2S)-2-[(3S)-3-[[2-(5-chloro-2-thienyl)ethyl]sulfonyl]amino]-2-oxo-1-pyrrolidinyl]-3-(1-methylethoxy)-1-oxopropyl]-(9CI) (CA INDEX NAME)


Absolute stereochemistry.

L4 ANSWER 6 OF 9 HCAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 711019-32-8 HCAPLUS
 CN Morpholine, 4-[(2S)-2-[(3S)-3-[[2-(5-chloro-2-thienyl)ethyl]sulfonyl]amino]-2-oxo-1-pyrrolidinyl]-3-ethoxy-1-oxopropyl]-(9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 711019-33-9 HCAPLUS
 CN Morpholine, 4-[(2S)-2-[(3S)-3-[[2-(4-chlorophenyl)ethyl]sulfonyl]amino]-2-oxo-1-pyrrolidinyl]-3-ethoxy-1-oxopropyl]-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 711019-34-0 HCAPLUS
 CN Morpholine, 4-[(2S)-2-[(3S)-3-[[((1E)-2-(5-chloro-2-thienyl)-1-propenyl)sulfonyl]amino]-2-oxo-1-pyrrolidinyl]-3-ethoxy-1-oxopropyl]-(9CI) (CA INDEX NAME)


Absolute stereochemistry.
 Double bond geometry as shown.

L4 ANSWER 6 OF 9 HCAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 711019-35-1 HCAPLUS
 CN Morpholine, 4-[(2S)-2-[(3S)-3-[[2-(5-chloro-2-thienyl)ethyl]sulfonyl]amino]-2-oxo-1-pyrrolidinyl]-4-methoxy-1-oxobutyl]-(9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 711019-36-2 HCAPLUS
 CN Morpholine, 4-[(2S)-2-[(3S)-3-[[2-(4-chlorophenyl)ethyl]sulfonyl]amino]-2-oxo-1-pyrrolidinyl]-3-methoxy-1-oxopropyl]-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 711019-37-3 HCAPLUS
 CN Morpholine, 4-[(2S)-2-[(3S)-3-[[2-(5-chloro-2-thienyl)ethyl]sulfonyl]amino]-2-oxo-1-pyrrolidinyl]-1-oxo-3-(4-pyridinyl)propyl]-(9CI) (CA INDEX NAME)


Absolute stereochemistry.

L4 ANSWER 6 OF 9 HCAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 711019-38-4 HCAPLUS
 CN Morpholine, 4-[(2S)-2-[(3S)-3-[[2-(5-chloro-2-thienyl)ethyl]sulfonyl]amino]-2-oxo-1-pyrrolidinyl]-1-oxo-3-(3-pyridinyl)propyl]-(9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 711019-39-5 HCAPLUS
 CN Morpholine, 4-[(2S)-2-[(3S)-3-[[2-(5-chloro-2-thienyl)ethyl]sulfonyl]amino]-2-oxo-1-pyrrolidinyl]-3-pyridinylacetyl]-(9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 711019-40-8 HCAPLUS
 CN Morpholine, 4-[(2S)-2-[(3S)-3-[[2-(5-chloro-2-thienyl)ethyl]sulfonyl]amino]-2-oxo-1-pyrrolidinyl]-4-(dimethylamino)-1-oxobutyl]-(9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 711019-41-9 HCAPLUS
 CN Morpholine, 4-[(2S)-2-[(3S)-3-[[2-(5-chloro-2-thienyl)ethyl]sulfonyl]amino]-2-oxo-1-pyrrolidinyl]-1-oxo-4-(1-piperidinyl)butyl - (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 711019-42-0 HCAPLUS
 CN Morpholine, 4-[(2S)-2-[(3S)-3-[[2-(5-chloro-2-thienyl)ethyl]sulfonyl]amino]-2-oxo-1-pyrrolidinyl]-4-(4-morpholinyl)-1-oxobutyl - (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 711019-43-1 HCAPLUS
 CN Morpholine, 4-[(2S)-2-[(3S)-3-[[1E]-2-(5-chloro-2-thienyl)-1-

Absolute stereochemistry.
 Double bond geometry as shown.




RN 711019-44-2 HCAPLUS
 CN Acetamide, 2-[[2-(5-chloro-2-thienyl)ethyl]sulfonyl][(3S)-1-[(1S)-1-(methoxymethyl)-2-(4-morpholinyl)-2-oxoethyl]-2-oxo-3-pyrrolidinyl]amino]-N,N-dimethyl - (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 711019-45-3 HCAPLUS
 CN Acetamide, 2-[[2-(5-chloro-2-thienyl)ethyl]sulfonyl][(3S)-1-[(1S)-1-(methoxymethyl)-2-(4-morpholinyl)-2-oxoethyl]-2-oxo-3-pyrrolidinyl]amino]-N-methyl - (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 711019-46-4 HCAPLUS
 CN Morpholine, 4-[(2S)-2-[(3S)-3-[[2-(4-chlorophenyl)ethyl]sulfonyl]amino]-2-oxo-1-pyrrolidinyl]-4-(methylsulfonyl)-1-oxobutyl - (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 711019-47-5 HCAPLUS
 CN Morpholine, 4-[(2S)-2-[(3S)-3-[[2-(5-chloro-2-thienyl)ethyl]sulfonyl]amino]-2-oxo-1-pyrrolidinyl]-1-oxo-3-(2-thienyl)propyl - (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 711019-48-6 HCAPLUS
 CN Morpholine, 4-[(2S)-2-[(3S)-3-[[2-(5-chloro-2-thienyl)propyl]sulfonyl]amino]-2-oxo-1-pyrrolidinyl]-1-oxopropyl - (9CI) (CA INDEX NAME)


Absolute stereochemistry.



IT 711018-04-1
 RL: RCT (Reactant); RACT (Reactant or reagent)
 (reactant) preparation of pyrrolidinone derive. useful as inhibitors of thrombin and factor Xa)

RN 711018-04-1 HCAPLUS
 CN 4-Morpholinobutanamide, β -[(3S)-3-[[2-(5-chloro-2-

Absolute stereochemistry.




L4 ANSWER 7 OF 9 HCPLUS COPYRIGHT 2007 ACS on STN
 ED Entered STN: 20 Dec 2002
 ACCESSION NUMBER: 2002:964381 HCPLUS
 DOCUMENT NUMBER: 138:39538
 TITLE: Sulfonylaminopyrrolidin-2-one-1-acetamides as
 inhibitors of Factor Xa
 INVENTOR(S): Chan, Chuen; Hamblin, Julie Nicole; Kelly, Henry
 Andreson; King, Nigel Paul; Mason, Andrew McMurtie;
 Patel, Vipulkumar Kantibhai; Senger, Stefan; Shah,
 Gita Punjabhai; Watson, Nigel Stephen; Weston, Helen
 Elisabeth; Whitworth, Caroline; Young, Robert John
 Glaxo Group Limited, UK
 PATENT ASSIGNEE(S): PCT Int. Appl., 210 pp.
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002100886	A1	20021219	WO 2002-GB2586	20020606
WO 2002100886	A8	20040205		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW	AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
EP 1395606	A1	20040310	EP 2002-738349	20020606
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
JP 2005508686	T	20050407	JP 2003-503652	20020606
US 2004152697	A1	20040805	US 2003-479534	20031203
US 7084139	B2	20060801		
US 2006160885	A1	20060720	US 2006-378947	20060317
US 2006160886	A1	20060720	US 2006-384094	20060317
PRIORITY APPLN. INFO.:			GB 2001-14004	A 20010608
			WO 2002-GB2586	W 20020606
			US 2003-479534	A3 20031203

OTHER SOURCE(S): MARPAT 138:39538
 GI


L4 ANSWER 7 OF 9 HCPLUS COPYRIGHT 2007 ACS on STN (Continued)



AB Title compds. I [R1 = H, (un)substituted alkyl, alkenyl, alkynyl, Ph, heterocycl]; R2 = alkyl, CF3; NR3R4 = (un)substituted heterocyclic; RS = fused bicyclic, (un)substituted Ph, heteroarom., aralkyl, heteroacylalkyl) were prepared for use in the amelioration of a clin. condition for which a Factor Xa inhibitor is indicated (no data). Thus, 2-L-Met-OH was treated with H-L-Ala-OH and the dipeptide was cyclized with acid ion exchange to give tert-Bu [(2S)-2-[(3S)-3-benzylxycarbonylaminoo-2-oxopyrrolidin-1-yl]propanoate, which was deblocked and sulfonylated with 6-chloro-2-naphthalenesulfonyl chloride, followed by ester hydrolysis and amidation with morpholine to give the sulfonamide II.
 IT 478645-99-7 478646-01-4P 478646-76-3P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (preparation of sulfonylaminopyrrolidin-2-one-1-acetamides as inhibitors of Factor Xa)


RN 478645-99-7 HCPLUS
 CN 1H-Indole-1-carboxylic acid, 5-chloro-2-[(1S)-1-methyl-2-(4-morpholinyl)-2-oxoethyl]-2-oxo-3-pyrrolidinyl]sulfonyl)-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 478646-01-4 HCPLUS
 CN Morpholine, 4-[(2S)-2-[(3S)-3-[(ethenylsulfonyl)amino]-2-oxo-1-pyrrolidinyl]-1-oxopropyl] (9CI) (CA INDEX NAME)

L4 ANSWER 7 OF 9 HCPLUS COPYRIGHT 2007 ACS on STN (Continued)
 Absolute stereochemistry.



RN 478646-76-3 HCPLUS
 CN Morpholine, 4-[(2S)-2-[(3S)-3-[(1S)-2-[(4-chloro-3-[(1,1-dimethylethyl)diphenylsilyl]oxy)phenyl]ethenylsulfonyl]amino]-2-oxo-1-pyrrolidinyl-1-oxopropyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.
 Double bond geometry as shown.



IT 478636-52-1P 478642-49-8P 478644-13-2P
 478644-14-3P
 RL: RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
 (preparation of sulfonylaminopyrrolidin-2-one-1-acetamides as inhibitors of Factor Xa)


RN 478636-52-1 HCPLUS
 CN Morpholine, 4-[(2S)-2-[(3S)-3-[(6-chloro-2-naphthalenyl)sulfonyl]amino]-2-oxo-1-pyrrolidinyl-1-oxopropyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 478642-49-8 HCPLUS
 CN Glycine, N-[(6-chloro-2-naphthalenyl)sulfonyl]-N-[(3S)-1-[(1S)-1-methyl-2-(4-morpholinyl)-2-oxoethyl]-2-oxo-3-pyrrolidinyl]-, methyl ester (9CI) (CA INDEX NAME)

L4 ANSWER 7 OF 9 HCPLUS COPYRIGHT 2007 ACS on STN (Continued)
 Absolute stereochemistry.




RN 478644-13-2 HCPLUS
 CN Benzo[b]thiophene-2-sulfonamide, 5-chloro-N-[(1S)-1-methyl-2-(4-morpholinyl)-2-oxoethyl]-2-oxo-3-pyrrolidinyl- (CA INDEX NAME)

Absolute stereochemistry.



RN 478644-14-3 HCPLUS
 CN Benzo[b]thiophene-2-sulfonamide, 6-chloro-N-[(1S)-1-methyl-2-(4-morpholinyl)-2-oxoethyl]-2-oxo-3-pyrrolidinyl- (CA INDEX NAME)

Absolute stereochemistry.




IT 478636-88-3P 478636-90-7P 478636-92-9P
 478637-00-2P 478637-03-5P 478637-05-7P
 478637-07-0P 478637-09-1P 478637-11-5P
 478637-13-7P 478637-15-9P 478637-17-1P
 478637-19-3P 478637-21-7P 478637-24-0P
 478637-27-3P 478637-30-8P 478637-33-1P
 478637-36-4P 478637-39-7P 478637-58-0P
 478637-75-1P 478637-83-1P 478637-96-6P
 478637-98-9P 478638-02-7P 478638-04-9P
 478638-07-2P 478638-10-7P 478638-12-9P
 478638-14-1P 478638-16-3P 478638-18-5P
 478638-20-5P 478639-41-7P 478641-01-9P
 478641-03-1P 478641-05-3P 478641-09-7P
 478641-11-1P 478641-13-3P 478641-15-5P
 478641-40-6P 478641-42-8P 478641-44-0P
 478641-47-3P 478641-50-8P 478641-75-7P

L4 ANSWER 7 OF 9 HCAPLUS COPYRIGHT 2007 ACS on STN (Continued)

478642-30-7P 478642-39-6P 478642-41-0P
 478642-43-2P 478642-45-4P 478642-47-6P
 478642-51-2P 478642-53-4P 478642-59-0P
 478643-08-2P 478644-11-0P 478644-12-1P
 478644-15-4P 478644-16-5P 478644-17-6P
 478644-18-7P 478644-19-8P 478644-20-1P
 478644-21-2P 478644-22-3P 478644-23-4P
 478644-24-5P 478644-25-6P 478644-26-7P
 478644-27-8P 478644-45-0P 478644-54-1P
 478644-55-2P 478644-57-4P 478644-59-6P
 478644-61-0P 478644-62-1P 478644-69-8P
 478644-70-1P 478644-73-4P 478644-74-5P
 478644-75-6P 478644-76-7P 478644-82-5P
 RL: SPN (Synthetic preparation); THU (Theapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (prep. of sulfonylamino-*pyrrolidin-2-one*-1-acetamides as inhibitors of Factor Xa)


RN 478636-88-3 HCAPLUS
 CN Morpholine, 4-[(2S)-2-[(3S)-3-[(6-chloro-2-naphthalenyl)sulfonyl]amino]-2-oxo-1-pyrrolidinyl]-1-oxopropyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 478636-90-7 HCAPLUS
 CN Morpholine, 4-[(2S)-2-[(3S)-3-[(6-chloro-2-naphthalenyl)sulfonyl]amino]-2-oxo-1-pyrrolidinyl]-1-oxopropyl-, (1S,4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 478636-92-9 HCAPLUS
 CN Morpholine, 4-[(2S)-2-[(3S)-3-[(6-chloro-2-naphthalenyl)sulfonyl]amino]-2-oxo-1-pyrrolidinyl]-1-oxopropyl]-3-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L4 ANSWER 7 OF 9 HCAPLUS COPYRIGHT 2007 ACS on STN (Continued)


RN 478637-07-9 HCAPLUS
 CN 2-Morpholinocarboxamide, 4-[(2S)-2-[(3S)-3-[(6-chloro-2-naphthalenyl)sulfonyl]amino]-2-oxo-1-pyrrolidinyl]-1-oxopropyl]-N-methyl-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 478637-09-1 HCAPLUS
 CN 2-Morpholinocarboxamide, 4-[(2S)-2-[(3S)-3-[(6-chloro-2-naphthalenyl)sulfonyl]amino]-2-oxo-1-pyrrolidinyl]-1-oxopropyl]-N-methyl-, (2R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 478637-11-5 HCAPLUS
 CN Morpholine, 4-[(2S)-2-[(3S)-3-[(6-chloro-2-naphthalenyl)sulfonyl]amino]-2-oxo-1-pyrrolidinyl]-1-oxopropyl]-2-(1-pyrrolidinylcarbonyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 478637-13-7 HCAPLUS
 CN 2-Morpholinocarboxamide, 4-[(2S)-2-[(3S)-3-[(6-chloro-2-

L4 ANSWER 7 OF 9 HCAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 478637-00-2 HCAPLUS
 CN Morpholine, 4-[(2S)-2-[(3S)-3-[(6-chloro-2-naphthalenyl)sulfonyl]amino]-2-oxo-1-pyrrolidinyl]-1-oxopropyl]-3-(1-pyrrolidinylcarbonyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 478637-03-5 HCAPLUS
 CN Morpholine, 4-[(2S)-2-[(3S)-3-[(6-chloro-2-naphthalenyl)sulfonyl]amino]-2-oxo-1-pyrrolidinyl]-1-oxopropyl]-2-(methylsulfonyl)methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 478637-05-7 HCAPLUS
 CN Morpholine, 4-[(2S)-2-[(3S)-3-[(6-chloro-2-naphthalenyl)sulfonyl]amino]-2-oxo-1-pyrrolidinyl]-1-oxopropyl]-2-(methoxymethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


L4 ANSWER 7 OF 9 HCAPLUS COPYRIGHT 2007 ACS on STN (Continued)
 naphthalenylsulfonyl]amino]-2-oxo-1-pyrrolidinyl]-1-oxopropyl]-N,N-dimethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 478637-15-9 HCAPLUS
 CN 2-Morpholinocarboxamide, 4-[(2S)-2-[(3S)-3-[(6-chloro-2-naphthalenyl)sulfonyl]amino]-2-oxo-1-pyrrolidinyl]-1-oxopropyl]-N-(2-hydroxypropyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 478637-17-1 HCAPLUS
 CN 2-Morpholinocarboxamide, 4-[(2S)-2-[(3S)-3-[(6-chloro-2-naphthalenyl)sulfonyl]amino]-2-oxo-1-pyrrolidinyl]-1-oxopropyl]-N,N-bis(1-methylethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 478637-19-3 HCAPLUS
 CN Morpholine, 4-[(2S)-2-[(3S)-3-[(6-chloro-2-naphthalenyl)sulfonyl]amino]-2-oxo-1-pyrrolidinyl]-1-oxopropyl]-2-(1-piperidinylcarbonyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 478637-21-7 HCPLUS
 CN 2-Morpholinemethanamine, 4-[(2S)-2-[(3S)-3-[(6-chloro-2-naphthalenyl)sulfonyl]amino]-2-oxo-1-pyrrolidinyl]-1-oxopropyl]-N-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 478637-24-0 HCPLUS
 CN Formic acid, compd. with 4-[(2S)-2-[(3S)-3-[(6-chloro-2-naphthalenyl)sulfonyl]amino]-2-oxo-1-pyrrolidinyl]-1-oxopropyl]-2-(1-pyrrolidinylmethyl)morpholine (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 478637-23-9
 CMF C26 H33 Cl N4 O5 S

Absolute stereochemistry.



CM 2

CRN 64-18-6
 CMF C H2 O2

O=CH-OH

CRN 64-18-6
 CMF C H2 O2


O=CH-OH

RN 478637-33-1 HCPLUS
 CN Formic acid, compd. with (2S)-4-[(2S)-2-[(3S)-3-[(6-chloro-2-naphthalenyl)sulfonyl]amino]-2-oxo-1-pyrrolidinyl]-1-oxopropyl]-N,N-dimethyl-2-morpholinemethanamine (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 478637-32-0
 CMF C24 H31 Cl N4 O5 S

Absolute stereochemistry.



CM 2

CRN 64-18-6
 CMF C H2 O2


O=CH-OH

RN 478637-36-4 HCPLUS
 CN Formic acid, compd. with 4-[(2S)-2-[(3S)-3-[(6-chloro-2-naphthalenyl)sulfonyl]amino]-2-oxo-1-pyrrolidinyl]-1-oxopropyl]-N,N-bis(1-methylethyl)-2-morpholinemethanamine (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 478637-35-3
 CMF C28 H39 Cl N4 O5 S

Absolute stereochemistry.




RN 478637-27-3 HCPLUS
 CN Formic acid, compd. with 4-[(2S)-2-[(3S)-3-[(6-chloro-2-naphthalenyl)sulfonyl]amino]-2-oxo-1-pyrrolidinyl]-1-oxopropyl]-N-(2-hydroxypropyl)-2-morpholinemethanamine (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 478637-26-2
 CMF C25 H33 Cl N4 O6 S

Absolute stereochemistry.



CM 2

CRN 64-18-6
 CMF C H2 O2


O=CH-OH

RN 478637-30-8 HCPLUS
 CN Formic acid, compd. with (2R)-4-[(2S)-2-[(3S)-3-[(6-chloro-2-naphthalenyl)sulfonyl]amino]-2-oxo-1-pyrrolidinyl]-1-oxopropyl]-N,N-dimethyl-2-morpholinemethanamine (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 478637-29-5
 CMF C24 H31 Cl N4 O5 S

Absolute stereochemistry.



CM 2

CRN 64-18-6
 CMF C H2 O2


O=CH-OH

RN 478637-39-7 HCPLUS
 CN Formic acid, compd. with 4-[(2S)-2-[(3S)-3-[(6-chloro-2-naphthalenyl)sulfonyl]amino]-2-oxo-1-pyrrolidinyl]-1-oxopropyl]-2-(1-piperidinylmethyl)morpholine (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 478637-38-6
 CMF C27 H35 Cl N4 O5 S

Absolute stereochemistry.




CM 2

CRN 64-18-6
 CMF C H2 O2

O=CH-OH

RN 478637-58-0 HCPLUS
 CN Morpholine, 4-[(2S)-2-[(3S)-3-[(6-chloro-2-naphthalenyl)sulfonyl]amino]-2-oxo-1-pyrrolidinyl]-1-oxopropyl]-2,6-dimethyl-, (2R,6S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 478637-75-1 HCPLUS
 CN Morpholine, 4-[(2S)-2-[(3R)-3-[(6-chloro-2-naphthalenyl)sulfonyl]amino]-2-

10537646


L4 ANSWER 7 OF 9 HCAPLUS COPYRIGHT 2007 ACS on STN (Continued)
oxo-1-pyrrolidinyl-1-oxopropyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 478637-83-1 HCAPLUS
CN Morpholine, 4-[(2S)-2-[(3S)-3-[(5'-chloro[2,2'-bithiophen]-5-yl)sulfonyl]amino]-2-oxo-1-pyrrolidinyl-1-oxopropyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 478637-96-6 HCAPLUS
CN Morpholine, 4-[(2S)-2-[(3S)-3-[(1E)-2-(4-chlorophenyl)ethenyl]sulfonyl]amino]-2-oxo-1-pyrrolidinyl-1-oxopropyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.
Double bond geometry as shown.



RN 478637-98-8 HCAPLUS
CN Acetamide, 2-[(1E)-2-(4-chlorophenyl)ethenyl]sulfonyl]- (3S)-1-[(1S)-1-methyl-2-(4-morpholinyl)-2-oxoethyl]-2-oxo-3-pyrrolidinyl-amino)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L4 ANSWER 7 OF 9 HCAPLUS COPYRIGHT 2007 ACS on STN (Continued)
Double bond geometry as shown.



RN 478638-02-7 HCAPLUS
CN Acetamide, 2-[(5'-chloro[2,2'-bithiophen]-5-yl)sulfonyl]- (3S)-1-[(1S)-1-methyl-2-(4-morpholinyl)-2-oxoethyl]-2-oxo-3-pyrrolidinyl-amino)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 478638-04-9 HCAPLUS
CN Morpholine, 4-[(2S)-2-[(3S)-3-[(5'-chloro[2,2'-bithiophen]-5-yl)sulfonyl]- (cyanomethyl)amino]-2-oxo-1-pyrrolidinyl-1-oxopropyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L4 ANSWER 7 OF 9 HCAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 478638-07-2 HCAPLUS
CN Glycine, N-[(5'-chloro[2,2'-bithiophen]-5-yl)sulfonyl]-N-[(3S)-1-[(1S)-1-methyl-2-(4-morpholinyl)-2-oxoethyl]-2-oxo-3-pyrrolidinyl]-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 478638-10-7 HCAPLUS
CN Morpholine, 4-[(2S)-2-[(3S)-3-[(5'-chloro[2,2'-bithiophen]-5-yl)sulfonyl]- (2-oxobutyl)amino]-2-oxo-1-pyrrolidinyl-1-oxopropyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 478638-12-9 HCAPLUS
CN Glycine, N-[(5'-chloro[2,2'-bithiophen]-5-yl)sulfonyl]-N-[(3S)-1-[(1S)-1-methyl-2-(4-morpholinyl)-2-oxoethyl]-2-oxo-3-pyrrolidinyl]- (9CI) (CA INDEX NAME)


L4 ANSWER 7 OF 9 HCAPLUS COPYRIGHT 2007 ACS on STN (Continued)

Absolute stereochemistry.




RN 478638-14-1 HCAPLUS
CN Morpholine, 4-[(2S)-2-[(3S)-3-[(1E)-2-(4-chlorophenyl)ethenyl]sulfonyl]- (cyanomethyl)amino]-2-oxo-1-pyrrolidinyl-1-oxopropyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.




RN 478638-16-3 HCAPLUS
CN Morpholine, 4-[(2S)-2-[(3S)-3-[(1E)-2-(4-chlorophenyl)ethenyl]sulfonyl]- (2-oxobutyl)amino]-2-oxo-1-pyrrolidinyl-1-oxopropyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.




RN 478638-18-5 HCAPLUS
 CN Glycine, N-[(1S)-2-(4-chlorophenyl)ethenyl]sulfonyl]-N-[(3S)-1-[(1S)-1-methyl-2-(4-morpholinyl)-2-oxoethyl]-2-oxo-3-pyrrolidinyl]-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.
 Double bond geometry as shown.




RN 478638-20-9 HCAPLUS
 CN Glycine, N-[(1S)-2-(4-chlorophenyl)ethenyl]sulfonyl]-N-[(3S)-1-[(1S)-1-methyl-2-(4-morpholinyl)-2-oxoethyl]-2-oxo-3-pyrrolidinyl]- (CA INDEX NAME)

Absolute stereochemistry.
 Double bond geometry as shown.




RN 478639-41-7 HCAPLUS
 CN Morpholine, 4-[(2S)-2-[(3S)-3-[(6-chloro-2-naphthalenyl)sulfonyl]amino]-2-oxo-1-pyrrolidinyl]-1-oxopropyl]-2-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 478641-01-9 HCAPLUS
 CN Morpholine, 4-[(2S)-2-[(3S)-3-[(6-chloro-2-naphthalenyl)sulfonyl](3-furanyl)methyl]amino]-2-oxo-1-pyrrolidinyl]-1-oxopropyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 478641-03-1 HCAPLUS
 CN Morpholine, 4-[(2S)-2-[(3S)-3-[(6-chloro-2-naphthalenyl)sulfonyl](3-pyridinyl)methyl]amino]-2-oxo-1-pyrrolidinyl]-1-oxopropyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 478641-05-3 HCAPLUS
 CN Morpholine, 4-[(2S)-2-[(3S)-3-[(6-chloro-2-naphthalenyl)sulfonyl]ethylamino]-2-oxo-1-pyrrolidinyl]-1-oxopropyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 478641-09-7 HCAPLUS
 CN Morpholine, 4-[(2S)-2-[(3S)-3-[(6-chloro-2-naphthalenyl)sulfonyl](2-oxobutyl)amino]-2-oxo-1-pyrrolidinyl]-1-oxopropyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 478641-11-1 HCAPLUS
 CN Acetamide, 2-[(6-chloro-2-naphthalenyl)sulfonyl][(3S)-1-[(1S)-1-methyl-2-(4-morpholinyl)-2-oxoethyl]-2-oxo-3-pyrrolidinyl]amino)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 478641-13-3 HCAPLUS
 CN Morpholine, 4-[(2S)-2-[(3S)-3-[(6-chloro-2-naphthalenyl)sulfonyl](2-furanyl)methyl]amino]-2-oxo-1-pyrrolidinyl]-1-oxopropyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 478641-15-5 HCAPLUS
 CN Morpholine, 4-[(2S)-2-[(3S)-3-[(6-chloro-2-naphthalenyl)sulfonyl](2-thiazolyl)methyl]amino]-2-oxo-1-pyrrolidinyl]-1-oxopropyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 478641-40-6 HCAPLUS
 CN Acetamide, 2-[(6-chloro-2-naphthalenyl)sulfonyl][(3S)-1-[(1S)-2-[(2R,6S)-2,6-dimethyl-4-morpholinyl]-1-methyl-2-oxoethyl]-2-oxo-3-pyrrolidinyl]amino)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 478641-42-8 HCPLUS
 CN Acetamide, 2-[(6-chloro-2-naphthalenyl)sulfonyl][(3S)-1-[(1S)-1-methyl-2-(15,4S)-2-oxa-5-azabicyclo[2.2.1]hept-5-yl-2-oxoethyl]-2-oxo-3-pyrrolidinyl]amino]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 478641-44-0 HCPLUS
 CN Morpholine, 4-[(2S)-2-[(3S)-3-[(6-chloro-2-naphthalenyl)sulfonyl][(2-methyl-4-thiazolyl)methyl]amino]-2-oxo-1-pyrrolidinyl]-1-oxopropyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 478641-47-3 HCPLUS
 CN Formic acid, compd. with 4-[(2S)-2-[(3S)-3-[(6-chloro-2-naphthalenyl)sulfonyl](2-pyridinylmethyl)amino]-2-oxo-1-pyrrolidinyl]-1-oxopropyl]morpholine (1:1) (7CI, 8CI, 9CI) (CA INDEX NAME)


CM 2

CRN 64-18-6
 CMF C H2 O2

O=CH-OH


RN 478641-75-7 HCPLUS
 CN Morpholine, 4-[(2R)-2-[(3S)-3-[(6-chloro-2-naphthalenyl)sulfonyl]amino]-2-oxo-1-pyrrolidinyl]-1-oxopropyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 478642-30-7 HCPLUS
 CN Morpholine, 4-[(2R)-2-[(3S)-3-[(6-chloro-2-naphthalenyl)sulfonyl]methyl]amino]-2-oxo-1-pyrrolidinyl]-1-oxopropyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 478642-39-6 HCPLUS
 CN Morpholine, 4-[(2S)-2-[(3S)-3-[(6-chloro-2-naphthalenyl)sulfonyl](cyanomethyl)amino]-2-oxo-1-pyrrolidinyl]-1-oxopropyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 478642-41-0 HCPLUS
 CN Morpholine, 4-[(2S)-2-[(3S)-3-[(6-chloro-2-naphthalenyl)sulfonyl]methyl]amino]-2-oxo-1-pyrrolidinyl]-1-oxopropyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

CM 1

CRN 478641-46-2
 CMF C27 H29 Cl N4 O5 S

Absolute stereochemistry.



CM 2

CRN 64-18-6
 CMF C H2 O2



O=CH-OH

RN 478641-50-8 HCPLUS
 CN Formic acid, compd. with 4-[(2S)-2-[(3S)-3-[(6-chloro-2-naphthalenyl)sulfonyl](4-pyridinylmethyl)amino]-2-oxo-1-pyrrolidinyl]-1-oxopropyl]morpholine (1:1) (9CI) (CA INDEX NAME)

CM 1


CRN 478641-49-5
 CMF C27 H29 Cl N4 O5 S

Absolute stereochemistry.




RN 478642-43-2 HCPLUS
 CN Morpholine, 4-[(2S)-2-[(3S)-3-[(6-chloro-2-naphthalenyl)sulfonyl](3,3-dimethyl-2-oxobutyl)amino]-2-oxo-1-pyrrolidinyl]-1-oxopropyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 478642-45-4 HCPLUS
 CN Acetamide, 2-[(6-chloro-2-naphthalenyl)sulfonyl][(3S)-1-[(1S)-1-methyl-2-(4-morpholinyl)-2-oxoethyl]-2-oxo-3-pyrrolidinyl]amino]-N-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 478642-47-6 HCPLUS
 CN Morpholine, 4-[(2S)-2-[(3S)-3-[(6-chloro-2-naphthalenyl)sulfonyl]-2-propenylamino]-2-oxo-1-pyrrolidinyl]-1-oxopropyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 478642-51-2 HCAPLUS
 CN Glycine, N-[(6-chloro-2-naphthalenyl)sulfonyl]-N-[(3S)-1-[(1S)-1-methyl-2-(4-morpholinyl)-2-oxoethyl]-2-oxo-3-pyrrolidinyl]-, ethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 478642-53-4 HCAPLUS
 CN Glycine, N-[(6-chloro-2-naphthalenyl)sulfonyl]-N-[(3S)-1-[(1S)-1-methyl-2-(4-morpholinyl)-2-oxoethyl]-2-oxo-3-pyrrolidinyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 478642-59-0 HCAPLUS
 CN Glycine, N-[(6-chloro-2-naphthalenyl)sulfonyl]-N-[(3S)-1-[(1S)-1-methyl-2-(4-morpholinyl)-2-oxoethyl]-2-oxo-3-pyrrolidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 478643-08-2 HCAPLUS
 CN Morpholine, 4-[(2R)-2-[(3R)-3-[(6-chloro-2-naphthalenyl)sulfonyl]amino]-2-oxo-1-pyrrolidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 478644-11-0 HCAPLUS
 CN 2-Benzofuransulfonamide, 5-chloro-N-[(3S)-1-[(1S)-1-methyl-2-(4-morpholinyl)-2-oxoethyl]-2-oxo-3-pyrrolidinyl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 478644-12-1 HCAPLUS
 CN Morpholine, 4-[(2S)-2-[(3S)-3-[(1E)-2-(5-chloro-2-thienyl)ethenyl]sulfonyl]amino]-2-oxo-1-pyrrolidinyl]-1-oxopropyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
 Double bond geometry as shown.




RN 478644-15-4 HCAPLUS
 CN Morpholine, 4-[(2S)-2-[(3S)-3-[(5-chloro-3-methylbenzo[b]thien-2-yl)sulfonyl]amino]-2-oxo-1-pyrrolidinyl]-1-oxopropyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 478644-16-5 HCAPLUS
 CN Morpholine, 4-[(2S)-2-[(3S)-3-[(3-cyanophenyl)sulfonyl]amino]-2-oxo-1-pyrrolidinyl]-1-oxopropyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 478644-17-6 HCAPLUS
 CN Morpholine, 4-[(2S)-2-[(3S)-3-[(4-cyanophenyl)sulfonyl]amino]-2-oxo-1-pyrrolidinyl]-1-oxopropyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 478644-18-7 HCAPLUS
 CN Morpholine, 4-[(2S)-2-[(3S)-3-[(5-(5-chloro-1,3,4-thiadiazol-2-yl)-2-thienyl)sulfonyl]amino]-2-oxo-1-pyrrolidinyl]-1-oxopropyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 478644-19-8 HCAPLUS
 CN Morpholine, 4-[(2S)-2-[(3S)-3-[(6-chlorobenzo[b]thien-2-yl)sulfonyl]-2-oxobutyl]amino]-2-oxo-1-pyrrolidinyl]-1-oxopropyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 478644-20-1 HCAPLUS
 CN Acetamide, 2-[(6-chlorobenzo[b]thien-2-yl)sulfonyl]-[(3S)-1-[(1S)-1-methyl-2-(4-morpholinyl)-2-oxoethyl]-2-oxo-3-pyrrolidinyl]amino]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 478644-21-2 HCAPLUS
 CN Morpholine, 4-[(2S)-2-[(3S)-3-[(6-chlorobenzylsulfonyl)(2-oxobutyl)amino]-2-oxo-1-pyrrolidinyl]-1-oxopropyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 478644-22-3 HCAPLUS
 CN Acetamide, 2-[(4-chlorobenzylsulfonyl)(3S)-1-[(1S)-1-methyl-2-(4-morpholinyl)-2-oxoethyl]-2-oxo-3-pyrrolidinyl]amino]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 478644-23-4 HCAPLUS
 CN Morpholine, 4-[(2S)-2-[(3S)-3-[(6-chloro-2-naphthalenylsulfonyl)phenylamino]-2-oxo-1-pyrrolidinyl]-1-oxopropyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 478644-27-8 HCAPLUS
 CN Morpholine, 4-[(2S)-2-[(3S)-3-[(6-chloro-2-naphthalenylsulfonyl)-3-thienylamino]-2-oxo-1-pyrrolidinyl]-1-oxopropyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 478644-45-0 HCAPLUS
 CN 9-Oxa-3,7-diazabicyclo[3.3.1]nonane, 3-[(2S)-2-[(3S)-3-[(6-chloro-2-naphthalenylsulfonyl)amino]-2-oxo-1-pyrrolidinyl]-1-oxopropyl]-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1


CRN 478644-44-9
 CMF C23 H27 Cl N4 O5 S

Absolute stereochemistry.




CM 2

CRN 76-05-1
 CMF C2 H F3 O2




RN 478644-24-5 HCAPLUS
 CN Morpholine, 4-[(2S)-2-[(3S)-3-[(6-chloro-2-naphthalenylsulfonyl)(4-fluorophenyl)amino]-2-oxo-1-pyrrolidinyl]-1-oxopropyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 478644-25-6 HCAPLUS
 CN Morpholine, 4-[(2S)-2-[(3S)-3-[(6-chloro-2-naphthalenylsulfonyl)-2-oxo-1-pyrrolidinyl]-1-oxopropyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 478644-26-7 HCAPLUS
 CN Morpholine, 4-[(2S)-2-[(3S)-3-[(6-chloro-2-naphthalenylsulfonyl)-3-pyridinylamino]-2-oxo-1-pyrrolidinyl]-1-oxopropyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 478644-54-1 HCAPLUS
 CN Morpholine, 4-[(2S)-2-[(3S)-3-[(1E)-2-(3-chloro-4-hydroxyphenyl)ethenyl]sulfonyl]amino]-2-oxo-1-pyrrolidinyl]-1-oxopropyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
 Double bond geometry as shown.



RN 478644-55-2 HCAPLUS
 CN Morpholine, 4-[(2S)-2-[(3S)-3-[(1E)-2-(4-chloro-3-hydroxyphenyl)ethenyl]sulfonyl]amino]-2-oxo-1-pyrrolidinyl]-1-oxopropyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
 Double bond geometry as shown.



RN 478644-57-4 HCAPLUS
 CN Formic acid, compd. with 4-[(2S)-2-[(3S)-3-[(6-chloro-2-naphthalenylsulfonyl)(2-(4-morpholinyl)ethyl)amino]-2-oxo-1-pyrrolidinyl]-1-oxopropyl]morpholine (1:1) (9CI) (CA INDEX NAME)


CM 1

10537646

L4 ANSWER 7 OF 9 HCAPLUS COPYRIGHT 2007 ACS on STN (Continued)

CRN 478644-56-3
CNMF C27 H35 Cl N4 O6 S

Absolute stereochemistry.




CM 2
CRN 64-18-6
CNMF C H2 O2

O=CH-OH


RN 478644-59-6 HCAPLUS
CN Formic acid, compd. with 4-[(2S)-2-[(3S)-3-[(6-chloro-2-naphthalenyl)sulfonyl][2-(1-pyrrolidinyl)ethyl]amino]-2-oxo-1-pyrrolidinyl]-1-oxopropyl]morpholine (1:1) (9CI) (CA INDEX NAME)
CM 1

CRN 478644-58-5
CNMF C27 H35 Cl N4 O5 S

Absolute stereochemistry.




L4 ANSWER 7 OF 9 HCAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 478644-69-8 HCAPLUS
CN 1H-Indole-2-sulfonamide, 5-chloro-N-[(3S)-1-[(1S)-1-methyl-2-(4-morpholinyl)-2-oxoethyl]-2-oxo-3-pyrrolidinyl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 478644-70-1 HCAPLUS
CN 2-Benzothiazolesulfonamide, 6-chloro-N-[(3S)-1-[(1S)-1-methyl-2-(4-morpholinyl)-2-oxoethyl]-2-oxo-3-pyrrolidinyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 478644-73-4 HCAPLUS
CN Morpholine, 4-[(2S)-2-[(3S)-3-[[5-chlorothieno[2,3-b]pyridin-2-yl]sulfonyl]amino]-2-oxo-1-pyrrolidinyl]-1-oxopropyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 478644-74-5 HCAPLUS
CN Morpholine, 4-[(2S)-2-[(3S)-3-[[5-chlorothieno[2,3-b]pyridin-2-yl]sulfonyl]amino]-2-oxo-1-pyrrolidinyl]-1-oxopropyl]- (9CI) (CA INDEX NAME)

L4 ANSWER 7 OF 9 HCAPLUS COPYRIGHT 2007 ACS on STN (Continued)

CM 2
CRN 64-18-6
CNMF C H2 O2


O=CH-OH

RN 478644-61-0 HCAPLUS
CN Formic acid, compd. with 4-[(2S)-2-[(3S)-3-[(6-chloro-2-naphthalenyl)sulfonyl][2-(dimethylamino)ethyl]amino]-2-oxo-1-pyrrolidinyl]-1-oxopropyl]morpholine (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 478644-60-9
CNMF C25 H33 Cl N4 O5 S

Absolute stereochemistry.



CM 2
CRN 64-18-6
CNMF C H2 O2


O=CH-OH

RN 478644-62-1 HCAPLUS
CN Acetamide, N-[2-[(6-chloro-2-naphthalenyl)sulfonyl][3S]-1-[(1S)-1-methyl-2-(4-morpholinyl)-2-oxoethyl]-2-oxo-3-pyrrolidinyl]aminoethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


L4 ANSWER 7 OF 9 HCAPLUS COPYRIGHT 2007 ACS on STN (Continued)

Absolute stereochemistry.




RN 478644-75-6 HCAPLUS
CN Morpholine, 4-[(2S)-2-[(3S)-3-[[6-chlorothieno[3,2-b]pyridin-2-yl]sulfonyl]amino]-2-oxo-1-pyrrolidinyl]-1-oxopropyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 478644-76-7 HCAPLUS
CN Morpholine, 4-[(2S)-2-[(3S)-3-[[[(1E)-2-(5-chloro-2-thienyl)ethyl]sulfonyl]methylamino]-2-oxo-1-pyrrolidinyl]-1-oxopropyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.




RN 478644-82-5 HCAPLUS
CN Formic acid, compd. with 4-[(2S)-2-[(3S)-3-[(6-chloro-2-naphthalenyl)sulfonyl][3-pyridinylmethyl]amino]-2-oxo-1-pyrrolidinyl]-1-oxopropyl]morpholine (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 478641-03-1
CNMF C27 H29 Cl N4 O5 S

Absolute stereochemistry.



CM 2


CRN 64-18-6
CMF C H2 O2

O=CH-OH

REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 8 OF 9 HCPLUS COPYRIGHT 2007 ACS on STN (Continued)
 ED Entered STN: 20 Dec 2002
 ACCESSION NUMBER: 2002-964327 HCPLUS
 DOCUMENT NUMBER: 138:39537
 TITLE: Preparation of 3-sulfonylaminopyrrolidine-1-acetamides as Factor Xa inhibitors
 INVENTOR(S): Chan, Chuen; Hamblin, Julie Nicole; Kelly, Henry; Anderson, King, Nigel Paul; Mason, Andrew McMurtie; Patel, Vipulmane; Kantibhai, Senger, Stefani; Shah, Gita; Punjabhai, Watson, Nigel Stephen; Weston, Helen; Elisabeth Whitworth, Caroline; Young, Robert John; Glaxo Group Limited, UK
 PATENT ASSIGNEE(S): PCT Int. Appl., 85 pp.
 SOURCE: CODEN: PIIXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002100830	A1	20021219	WO 2002-GB2721	20020606
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MW, MX, NO, NL, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW				
RU: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CH, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2449629	A1	20021219	CA 2002-2449629	20020606
EP 1395553	A1	20040310	EP 2002-738368	20020606
EP 1395553	B1	20050216		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
HU 200400156	A	20040728	HU 2004-156	20020606
BR 2002010207	A	20040803	BR 2002-10207	20020606
CN 1538955	A	20041020	CN 2002-815400	20020606
JP 2004537530	T	20041216	JP 2003-503599	20020606
AT 289294	T	20050315	AT 2002-738368	20020606
PT-1395553	T	20050630	PT 2002-738368	20020606
ES 2235050	T3	20050701	ES 2002-2738368	20020606
NZ 530004	A	20050826	NZ 2002-530004	20020606
ZA 2003009367	A	20040802	ZA 2003-9367	20031202
US 2005107379	A1	20050519	US 2003-479545	20031202
US 7186717	B2	20070306		
IN 2003DN02079	A	20070112	IN 2003-ON2079	20031203
HK 1063471	A1	20050909	HK 2004-106291	20040823
PRIORITY APPLN. INFO.:			GB 2001-14005	A 20010608
OTHER SOURCE(S):	MARPAT	138:39537	WO 2002-GB2721	W 20020606
GI				



AB Title compds. I [R1 = H, (un)substituted alkyl, alkenyl, Ph, heteroarom.; R2 = alkyl, CF3; R3 = (un)substituted morpholino; A = (un)substituted naphthyl, phenylalkyl, NCCOR, thiencylalkyl, thiopyridinyl, benzothiazolyl, benzofuryl, benzothienyl, indolyl, bithienyl, thiadiazolylthienyl] were prepared for use in the amelioration of a clin. condition for which a Factor Xa inhibitor is indicated. An example is 6-chloro-N-[3S]-1-[1S]-1-methyl-2-morpholin-4-yl-2-oxoethyl]-2-oxopyrrolidin-3-yl]naphthalene-2-sulfonamide, for which a synthesis is described. All of the synthetic example compds. tested exhibited IC50 values for in vitro inhibition of Factor Xa of < 60 μ M. Preferably compds. have an IC50 value of < 2 μ M (more preferably < 0.1 μ M).


IT 478645-99-7P 478646-01-4P 478646-76-3P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent); (preparation of (sulfonylamino)pyrrolidineacetamides as Factor Xa inhibitors)

RN 478645-99-7 HCAPLUS


CN 1H-Indole-1-carboxylic acid, 5-chloro-2-[(3S)-1-[(1S)-1-methyl-2-(4-morpholinyl)-2-oxoethyl]-2-oxo-3-pyrrolidinyl]amino]-2-oxo-1,1-dimethyl-ethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 478646-01-4 HCAPLUS
 CN Morpholine, 4-[(2S)-2-[(3S)-3-[(ethenylsulfonyl)amino]-2-oxo-1-pyrrolidinyl]-1-oxopropyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 478646-76-3 HCAPLUS
 CN Morpholine, 4-[(2S)-2-[(3S)-3-[(1E)-2-[(4-chloro-3-[(1,1-dimethylethyl)diphenylsilyl]oxyl)phenyl]ethenyl]sulfonyl]amino]-2-oxo-1-pyrrolidinyl]-1-oxopropyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.


IT 478636-52-1P 478642-49-8P 478644-12-1P

RL: RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses); (preparation of (sulfonylamino)pyrrolidineacetamides as Factor Xa inhibitors)

RN 478636-52-1 HCAPLUS


CN Morpholine, 4-[(2S)-2-[(3S)-3-[(6-chloro-2-naphthalenyl)sulfonyl]amino]-2-oxo-1-pyrrolidinyl]-1-oxopropyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 478642-49-8 HCAPLUS
 CN Glycine, N-[(6-chloro-2-naphthalenyl)sulfonyl]-N-[(3S)-1-[(1S)-1-methyl-2-(4-morpholinyl)-2-oxoethyl]-2-oxo-3-pyrrolidinyl]-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 478644-12-1 HCAPLUS
 CN Morpholine, 4-[(2S)-2-[(3S)-3-[[[(1E)-2-(5-chloro-2-phenyl)ethenyl]sulfonyl]amino]-2-oxo-1-pyrrolidinyl]-1-oxopropyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
 Double bond geometry as shown.




IT 478636-88-3P 478636-92-9P 478637-00-2P
 478637-03-5P 478637-05-7P 478637-07-9P
 478637-09-1P 478637-11-5P 478637-13-7P
 478637-15-9P 478637-17-1P 478637-19-3P
 478637-21-7P 478637-24-0P 478637-27-3P
 478637-29-5P 478637-32-0P 478637-35-3P
 478637-39-7P 478637-58-0P 478637-75-1P
 478637-83-1P 478637-96-6P 478638-04-9P
 478638-07-2P 478638-10-7P 478638-12-9P
 478638-14-1P 478638-16-3P 478638-18-5P
 478638-26-9P 478639-41-7P 478641-01-9P
 478641-05-3P 478641-09-7P 478641-13-3P
 478641-15-5P 478641-44-0P 478641-47-3P
 478641-50-8P 478641-75-7P 478642-30-7P
 478642-39-6P 478642-41-0P 478642-43-2P
 478642-45-4P 478642-47-6P 478642-51-2P
 478642-53-4P 478642-59-0P 478643-08-2P
 478644-11-0P 478644-13-2P 478644-14-3P
 478644-15-4P 478644-16-5P 478644-17-6P
 478644-18-7P 478644-19-8P 478644-21-2P
 478644-23-4P 478644-24-5P 478644-25-6P
 478644-26-7P 478644-27-8P 478644-54-1P
 478644-55-2P 478644-57-4P 478644-59-6P
 478644-61-0P 478644-62-1P 478644-69-8P
 478644-70-1P 478644-73-4P 478644-74-5P
 478644-75-6P 478644-76-7P 478644-82-5P
 478825-55-7P 478825-83-1P 478825-85-3P

Absolute stereochemistry.




RN 478637-05-7 HCAPLUS
 CN Morpholine, 4-[(2S)-2-[(3S)-3-[[[(6-chloro-2-naphthalenyl)sulfonyl]amino]-2-oxo-1-pyrrolidinyl]-1-oxopropyl]-2-(methoxymethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 478637-07-9 HCAPLUS
 CN 2-Morpholinocarboxamide, 4-[(2S)-2-[(3S)-3-[[[(6-chloro-2-naphthalenyl)sulfonyl]amino]-2-oxo-1-pyrrolidinyl]-1-oxopropyl]-N-methyl-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 478637-09-1 HCAPLUS
 CN 2-Morpholinocarboxamide, 4-[(2S)-2-[(3S)-3-[[[(6-chloro-2-naphthalenyl)sulfonyl]amino]-2-oxo-1-pyrrolidinyl]-1-oxopropyl]-N-methyl-, (2R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 478636-88-3 HCAPLUS
 CN Morpholine, 4-[(2S)-2-[(3S)-3-[[[(6-chloro-2-naphthalenyl)sulfonyl]amino]-2-oxo-1-pyrrolidinyl]-1-oxopropyl]-2,6-dimethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 478636-92-9 HCAPLUS
 CN Morpholine, 4-[(2S)-2-[(3S)-3-[[[(6-chloro-2-naphthalenyl)sulfonyl]amino]-2-oxo-1-pyrrolidinyl]-1-oxopropyl]-3-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 478637-00-2 HCAPLUS
 CN Morpholine, 4-[(2S)-2-[(3S)-3-[[[(6-chloro-2-naphthalenyl)sulfonyl]amino]-2-oxo-1-pyrrolidinyl]-1-oxopropyl]-3-(1-pyrrolidinylcarbonyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 478637-03-5 HCAPLUS
 CN Morpholine, 4-[(2S)-2-[(3S)-3-[[[(6-chloro-2-naphthalenyl)sulfonyl]amino]-2-


RN 478637-11-5 HCAPLUS
 CN Morpholine, 4-[(2S)-2-[(3S)-3-[[[(6-chloro-2-naphthalenyl)sulfonyl]amino]-2-oxo-1-pyrrolidinyl]-2-(1-pyrrolidinylcarbonyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 478637-13-7 HCAPLUS
 CN 2-Morpholinocarboxamide, 4-[(2S)-2-[(3S)-3-[[[(6-chloro-2-naphthalenyl)sulfonyl]amino]-2-oxo-1-pyrrolidinyl]-1-oxopropyl]-N,N-dimethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 478637-15-9 HCAPLUS
 CN 2-Morpholinocarboxamide, 4-[(2S)-2-[(3S)-3-[[[(6-chloro-2-naphthalenyl)sulfonyl]amino]-2-oxo-1-pyrrolidinyl]-1-oxopropyl]-N-(2-hydroxypropyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 478637-17-1 HCAPLUS
 CN 2-Morpholinocarboxamide, 4-[(2S)-2-[(3S)-3-[[[(6-chloro-2-naphthalenyl)sulfonyl]amino]-2-oxo-1-pyrrolidinyl]-1-oxopropyl]-N,N-bis(1-methylethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 478637-19-3 HCAPLUS
 CN Morpholine, 4-[(2S)-2-[(3S)-3-[(6-chloro-2-naphthalenyl)sulfonyl]amino]-2-oxo-1-pyrrolidinyl-1-oxopropyl]-2-(1-piperidinylcarbonyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 478637-21-7 HCAPLUS
 CN 2-Morpholinemethanamine, 4-[(2S)-2-[(3S)-3-[(6-chloro-2-naphthalenyl)sulfonyl]amino]-2-oxo-1-pyrrolidinyl-1-oxopropyl]-N-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 478637-24-0 HCAPLUS
 CN Formic acid, compd. with 4-[(2S)-2-[(3S)-3-[(6-chloro-2-naphthalenyl)sulfonyl]amino]-2-oxo-1-pyrrolidinyl-1-oxopropyl]-2-(1-pyrrolidinylmethyl)morpholine (1:1) (9CI) (CA INDEX NAME)

CM 1


CRN 478637-23-9
 CMF C26 H33 Cl N4 O5 S

Absolute stereochemistry.




RN 478637-32-0 HCAPLUS
 CN 2-Morpholinemethanamine, 4-[(2S)-2-[(3S)-3-[(6-chloro-2-naphthalenyl)sulfonyl]amino]-2-oxo-1-pyrrolidinyl-1-oxopropyl]-N,N-dimethyl-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 478637-35-3 HCAPLUS
 CN 2-Morpholinemethanamine, 4-[(2S)-2-[(3S)-3-[(6-chloro-2-naphthalenyl)sulfonyl]amino]-2-oxo-1-pyrrolidinyl-1-oxopropyl]-N,N-bis(1-methylethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 478637-39-7 HCAPLUS
 CN Formic acid, compd. with 4-[(2S)-2-[(3S)-3-[(6-chloro-2-naphthalenyl)sulfonyl]amino]-2-oxo-1-pyrrolidinyl-1-oxopropyl]-2-(1-piperidinylmethyl)morpholine (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 478637-38-6
 CMF C27 H35 Cl N4 O5 S

Absolute stereochemistry.



CM 2

CRN 64-18-6
 CMF C H2 O2


O=CH-OH

RN 478637-27-3 HCAPLUS
 CN Formic acid, compd. with 4-[(2S)-2-[(3S)-3-[(6-chloro-2-naphthalenyl)sulfonyl]amino]-2-oxo-1-pyrrolidinyl-1-oxopropyl]-N-(2-hydroxymethyl)-2-morpholinemethanamine (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 478637-26-2
 CMF C25 H33 Cl N4 O6 S

Absolute stereochemistry.




CM 2

CRN 64-18-6
 CMF C H2 O2

O=CH-OH

RN 478637-29-5 HCAPLUS
 CN 2-Morpholinemethanamine, 4-[(2S)-2-[(3S)-3-[(6-chloro-2-naphthalenyl)sulfonyl]amino]-2-oxo-1-pyrrolidinyl-1-oxopropyl]-N,N-dimethyl-, (2R)- (9CI) (CA INDEX NAME)




CM 2

CRN 64-18-6
 CMF C H2 O2

O=CH-OH


RN 478637-58-0 HCAPLUS
 CN Morpholine, 4-[(2S)-2-[(3S)-3-[(6-chloro-2-naphthalenyl)sulfonyl]amino]-2-oxo-1-pyrrolidinyl-1-oxopropyl]-2,6-dimethyl-, (2R,6S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 478637-75-1 HCAPLUS
 CN Morpholine, 4-[(2S)-2-[(3R)-3-[(6-chloro-2-naphthalenyl)sulfonyl]amino]-2-oxo-1-pyrrolidinyl-1-oxopropyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 478637-83-1 HCAPLUS
 CN Morpholine, 4-[(2S)-2-[(3S)-3-[(5'-chloro-2,2'-bithiophen)-5-yl)sulfonyl]amino]-2-oxo-1-pyrrolidinyl-1-oxopropyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 478637-96-6 HCPLUS
 CN Morpholine, 4-[(2S)-2-[(3S)-3-[(1E)-2-(4-chlorophenyl)ethenyl]sulfonyl]amino]-2-oxo-1-pyrrolidinyl-1-oxopropyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
 Double bond geometry as shown.




RN 478638-04-9 HCPLUS
 CN Morpholine, 4-[(2S)-2-[(3S)-3-[(5'-chloro[2,2'-bithiophen]-5-yl)sulfonyl](cyanomethyl)amino]-2-oxo-1-pyrrolidinyl-1-oxopropyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 478638-07-2 HCPLUS
 CN Glycine, N-[(5'-chloro[2,2'-bithiophen]-5-yl)sulfonyl]-N-[(3S)-1-[(1S)-1-methyl-2-(4-morpholinyl)-2-oxoethyl]-2-oxo-3-pyrrolidinyl]-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 478638-10-7 HCPLUS
 CN Morpholine, 4-[(2S)-2-[(3S)-3-[(5'-chloro[2,2'-bithiophen]-5-yl)sulfonyl](2-oxobutyl)amino]-2-oxo-1-pyrrolidinyl-1-oxopropyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 478638-12-9 HCPLUS
 CN Glycine, N-[(5'-chloro[2,2'-bithiophen]-5-yl)sulfonyl]-N-[(3S)-1-[(1S)-1-methyl-2-(4-morpholinyl)-2-oxoethyl]-2-oxo-3-pyrrolidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 478638-14-1 HCPLUS
 CN Morpholine, 4-[(2S)-2-[(3S)-3-[(1E)-2-(4-chlorophenyl)ethenyl]sulfonyl](cyanomethyl)amino]-2-oxo-1-pyrrolidinyl-1-oxopropyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
 Double bond geometry as shown.




RN 478638-16-3 HCPLUS
 CN Morpholine, 4-[(2S)-2-[(3S)-3-[(1E)-2-(4-chlorophenyl)ethenyl]sulfonyl](2-oxobutyl)amino]-2-oxo-1-pyrrolidinyl-1-oxopropyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
 Double bond geometry as shown.




RN 478638-18-5 HCPLUS
 CN Glycine, N-[(1E)-2-(4-chlorophenyl)ethenylsulfonyl]-N-[(3S)-1-[(1S)-1-methyl-2-(4-morpholinyl)-2-oxoethyl]-2-oxo-3-pyrrolidinyl]-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.
 Double bond geometry as shown.




RN 478638-20-9 HCPLUS
 CN Glycine, N-[(1E)-2-(4-chlorophenyl)ethenylsulfonyl]-N-[(3S)-1-[(1S)-1-methyl-2-(4-morpholinyl)-2-oxoethyl]-2-oxo-3-pyrrolidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
 Double bond geometry as shown.




RN 478639-41-7 HCPLUS
 CN Morpholine, 4-[(2S)-2-[(3S)-3-[(6-chloro-2-naphthalenyl)sulfonyl]amino]-2-oxo-1-pyrrolidinyl-1-oxopropyl]-2-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




L4 ANSWER 8 OF 9 HCAPLUS COPYRIGHT 2007 ACS on STN (Continued)
 RN 478641-01-9 HCAPLUS
 CN Morpholine, 4-[(2S)-2-[(3S)-3-[[6-chloro-2-naphthalenyl]sulfonyl](3-furanylmethyl)amino]-2-oxo-1-pyrrolidinyl]-1-oxopropyl]-(9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 478641-05-3 HCAPLUS
 CN Morpholine, 4-[(2S)-2-[(3S)-3-[[6-chloro-2-naphthalenyl]sulfonyl]ethylamino]-2-oxo-1-pyrrolidinyl]-1-oxopropyl]-(9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 478641-09-7 HCAPLUS
 CN Morpholine, 4-[(2S)-2-[(3S)-3-[[6-chloro-2-naphthalenyl]sulfonyl](2-oxobutyl)amino]-2-oxo-1-pyrrolidinyl]-1-oxopropyl]-(9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 478641-13-3 HCAPLUS
 CN Morpholine, 4-[(2S)-2-[(3S)-3-[[6-chloro-2-naphthalenyl]sulfonyl](2-furanylmethyl)amino]-2-oxo-1-pyrrolidinyl]-1-oxopropyl]-(9CI) (CA INDEX NAME)

L4 ANSWER 8 OF 9 HCAPLUS COPYRIGHT 2007 ACS on STN (Continued)
 Absolute stereochemistry.




RN 478641-15-5 HCAPLUS
 CN Morpholine, 4-[(2S)-2-[(3S)-3-[[6-chloro-2-naphthalenyl]sulfonyl](2-thiazolylmethyl)amino]-2-oxo-1-pyrrolidinyl]-1-oxopropyl]-(9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 478641-44-0 HCAPLUS
 CN Morpholine, 4-[(2S)-2-[(3S)-3-[[6-chloro-2-naphthalenyl]sulfonyl](2-methyl-4-thiazolyl)methylamino]-2-oxo-1-pyrrolidinyl]-1-oxopropyl]-(9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 478641-47-3 HCAPLUS
 CN Formic acid, compd. with 4-[(2S)-2-[(3S)-3-[[6-chloro-2-naphthalenyl]sulfonyl](2-pyridinylmethyl)amino]-2-oxo-1-pyrrolidinyl]-1-oxopropyl]morpholine (1:1) (7CI, 8CI, 9CI) (CA INDEX NAME)

L4 ANSWER 8 OF 9 HCAPLUS COPYRIGHT 2007 ACS on STN (Continued)

CM 1

CRN 478641-46-2
 CMF C27 H29 Cl N4 O5 S

Absolute stereochemistry.



CM 2

CRN 64-18-6
 CMF C H2 O2


O=CH-OH

RN 478641-50-8 HCAPLUS
 CN Formic acid, compd. with 4-[(2S)-2-[(3S)-3-[[6-chloro-2-naphthalenyl]sulfonyl](4-pyridinylmethyl)amino]-2-oxo-1-pyrrolidinyl]-1-oxopropyl]morpholine (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 478641-49-5
 CMF C27 H29 Cl N4 O5 S

Absolute stereochemistry.



CM 2


CRN 64-18-6

L4 ANSWER 8 OF 9 HCAPLUS COPYRIGHT 2007 ACS on STN (Continued)
 CMF C H2 O2

O=CH-OH


RN 478641-75-7 HCAPLUS
 CN Morpholine, 4-[(2R)-2-[(3S)-3-[[6-chloro-2-naphthalenyl]sulfonyl]amino]-2-oxo-1-pyrrolidinyl]-1-oxopropyl]-(9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 478642-30-7 HCAPLUS
 CN Morpholine, 4-[(2R)-2-[(3S)-3-[[6-chloro-2-naphthalenyl]sulfonyl]methylamino]-2-oxo-1-pyrrolidinyl]-1-oxopropyl]-(9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 478642-39-6 HCAPLUS
 CN Morpholine, 4-[(2S)-2-[(3S)-3-[[6-chloro-2-naphthalenyl]sulfonyl](cyanomethyl)amino]-2-oxo-1-pyrrolidinyl]-1-oxopropyl]-(9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 478642-41-0 HCAPLUS
 CN Morpholine, 4-[(2S)-2-[(3S)-3-[[6-chloro-2-naphthalenyl]sulfonyl]methylamino]-2-oxo-1-pyrrolidinyl]-1-oxopropyl]-(9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 478642-43-2 HCPLUS
 CN Morpholine, 4-[(2S)-2-[(3S)-3-[(6-chloro-2-naphthalenyl)sulfonyl]amino]-2-oxo-1-pyrrolidinyl]-1-oxopropyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 478642-45-4 HCPLUS
 CN Acetamide, 2-[(6-chloro-2-naphthalenyl)sulfonyl][(3S)-1-[(1S)-1-methyl-2-(4-morpholinyl)-2-oxoethyl]-2-oxo-3-pyrrolidinyl]amino]-N-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 478642-47-6 HCPLUS
 CN Morpholine, 4-[(2S)-2-[(3S)-3-[(6-chloro-2-naphthalenyl)sulfonyl]-2-propenylamino]-2-oxo-1-pyrrolidinyl]-1-oxopropyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 478642-51-2 HCPLUS
 CN Glycine, N-[(6-chloro-2-naphthalenyl)sulfonyl]-N-[(3S)-1-[(1S)-1-methyl-2-(4-morpholinyl)-2-oxoethyl]-2-oxo-3-pyrrolidinyl]-, ethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 478642-53-4 HCPLUS
 CN Glycine, N-[(6-chloro-2-naphthalenyl)sulfonyl]-N-[(3S)-1-[(1S)-1-methyl-2-(4-morpholinyl)-2-oxoethyl]-2-oxo-3-pyrrolidinyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 478642-59-0 HCPLUS
 CN Glycine, N-[(6-chloro-2-naphthalenyl)sulfonyl]-N-[(3S)-1-[(1S)-1-methyl-2-(4-morpholinyl)-2-oxoethyl]-2-oxo-3-pyrrolidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 478643-08-2 HCPLUS
 CN Morpholine, 4-[(2R)-2-[(3R)-3-[(6-chloro-2-naphthalenyl)sulfonyl]amino]-2-oxo-1-pyrrolidinyl]-1-oxopropyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 478644-11-0 HCPLUS
 CN 2-Benzofuranosulfonamide, 5-chloro-N-[(3S)-1-[(1S)-1-methyl-2-(4-morpholinyl)-2-oxoethyl]-2-oxo-3-pyrrolidinyl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 478644-13-2 HCPLUS
 CN Benzo[b]thiophene-2-sulfonamide, 5-chloro-N-[(3S)-1-[(1S)-1-methyl-2-(4-morpholinyl)-2-oxoethyl]-2-oxo-3-pyrrolidinyl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 478644-14-3 HCPLUS
 CN Benzo[b]thiophene-2-sulfonamide, 6-chloro-N-[(3S)-1-[(1S)-1-methyl-2-(4-

Absolute stereochemistry.




RN 478644-15-4 HCPLUS
 CN Morpholine, 4-[(2S)-2-[(3S)-3-[(5-chloro-3-methylbenzo[b]thien-2-yl)sulfonyl]amino]-2-oxo-1-pyrrolidinyl]-1-oxopropyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 478644-16-5 HCPLUS
 CN Morpholine, 4-[(2S)-2-[(3S)-3-[(3-cyanophenyl)sulfonyl]amino]-2-oxo-1-pyrrolidinyl]-1-oxopropyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 478644-17-6 HCPLUS
 CN Morpholine, 4-[(2S)-2-[(3S)-3-[(4-cyanophenyl)sulfonyl]amino]-2-oxo-1-pyrrolidinyl]-1-oxopropyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 478644-18-7 HCAPLUS
 CN Morpholine, 4-[(2S)-2-[(3S)-3-[[5-(5-chloro-1,3,4-thiadiazol-2-yl)-2-thienylsulfonyl]amino]-2-oxo-1-pyrrolidinyl]-1-oxopropyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 478644-19-8 HCAPLUS
 CN Morpholine, 4-[(2S)-2-[(3S)-3-[[6-chlorobenzo[b]thien-2-ylsulfonyl](2-oxobutyl)amino]-2-oxo-1-pyrrolidinyl]-1-oxopropyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 478644-21-2 HCAPLUS
 CN Morpholine, 4-[(2S)-2-[(3S)-3-[[5-chlorobenzo[b]thien-2-ylsulfonyl](2-oxobutyl)amino]-2-oxo-1-pyrrolidinyl]-1-oxopropyl]- (9CI) (CA INDEX NAME)




RN 478644-26-7 HCAPLUS
 CN Morpholine, 4-[(2S)-2-[(3S)-3-[[6-chloro-2-naphthalenylsulfonyl]3-pyridinylamino]-2-oxo-1-pyrrolidinyl]-1-oxopropyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 478644-27-8 HCAPLUS
 CN Morpholine, 4-[(2S)-2-[(3S)-3-[[6-chloro-2-naphthalenylsulfonyl]3-thienylamino]-2-oxo-1-pyrrolidinyl]-1-oxopropyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 478644-54-1 HCAPLUS
 CN Morpholine, 4-[(2S)-2-[(3S)-3-[[[(1E)-2-(3-chloro-4-hydroxyphenyl)ethenyl]sulfonyl]amino]-2-oxo-1-pyrrolidinyl]-1-oxopropyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.
 Double bond geometry as shown.

Absolute stereochemistry.




RN 478644-23-4 HCAPLUS
 CN Morpholine, 4-[(2S)-2-[(3S)-3-[[6-chloro-2-naphthalenylsulfonyl]phenylamino]-2-oxo-1-pyrrolidinyl]-1-oxopropyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 478644-24-5 HCAPLUS
 CN Morpholine, 4-[(2S)-2-[(3S)-3-[[6-chloro-2-naphthalenylsulfonyl](4-fluorophenyl)amino]-2-oxo-1-pyrrolidinyl]-1-oxopropyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 478644-25-6 HCAPLUS
 CN Morpholine, 4-[(2S)-2-[(3S)-3-[[6-chloro-2-naphthalenylsulfonyl]-4-pyridinylamino]-2-oxo-1-pyrrolidinyl]-1-oxopropyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 478644-55-2 HCAPLUS
 CN Morpholine, 4-[(2S)-2-[(3S)-3-[[[(1E)-2-(4-chloro-3-hydroxyphenyl)ethenyl]sulfonyl]amino]-2-oxo-1-pyrrolidinyl]-1-oxopropyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
 Double bond geometry as shown.




RN 478644-57-4 HCAPLUS
 CN Formic acid, compd. with 4-[(2S)-2-[(3S)-3-[[6-chloro-2-naphthalenylsulfonyl](2-(4-morpholinyl)ethyl)amino]-2-oxo-1-pyrrolidinyl]-1-oxopropyl]morpholine (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 478644-56-3
 CMF C27 H35 Cl N4 O6 S

Absolute stereochemistry.



CM 2

CRN 64-18-6
CMF C H2 O2

O= CH-OH


RN 478644-59-6 HCPLUS

CN Formic acid, compd. with 4-[(2S)-2-[(3S)-3-[(6-chloro-2-naphthalenylsulfonyl)2-(1-pyrrolidinyl)ethyl]amino]-2-oxo-1-pyrrolidinyl-1-oxopropyl]morpholine (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 478644-59-5
CMF C27 H35 Cl N4 O5 S


Absolute stereochemistry.



CM 2

CRN 64-18-6
CMF C H2 O2L4 ANSWER 8 OF 9 HCPLUS COPYRIGHT 2007 ACS on STN (Continued)
morpholinyl)-2-oxoethyl)-2-oxo-3-pyrrolidinyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 478644-70-1 HCPLUS

CN 2-Benzothiazolesulfonamide, 6-chloro-N-[(3S)-1-[(1S)-1-methyl-2-(4-morpholinyl)-2-oxoethyl]-2-oxo-3-pyrrolidinyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 478644-73-4 HCPLUS

CN Morpholine, 4-[(2S)-2-[(3S)-3-[(5-chlorothieno[2,3-b]pyridin-2-yl)sulfonyl]amino]-2-oxo-1-pyrrolidinyl-1-oxopropyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 478644-74-5 HCPLUS

CN Morpholine, 4-[(2S)-2-[(3S)-3-[(5-chlorothieno[2,3-b]pyridin-2-yl)sulfonyl]amino]-2-oxo-1-pyrrolidinyl-1-oxopropyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 478644-75-6 HCPLUS

O= CH-OH


RN 478644-61-0 HCPLUS

CN Formic acid, compd. with 4-[(2S)-2-[(3S)-3-[(6-chloro-2-naphthalenylsulfonyl)2-(dimethylamino)ethyl]amino]-2-oxo-1-pyrrolidinyl-1-oxopropyl]morpholine (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 478644-60-9
CMF C25 H33 Cl N4 O5 S

Absolute stereochemistry.



CM 2


CRN 64-18-6
CMF C H2 O2

O= CH-OH

RN 478644-62-1 HCPLUS

CN Acetamide, N-[2-[(6-chloro-2-naphthalenylsulfonyl)2-(4-morpholinyl)-2-oxoethyl]-2-oxo-3-pyrrolidinyl]amino]ethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 478644-69-8 HCPLUS

CN 1H-Indole-2-sulfonamide, 5-chloro-N-[(3S)-1-[(1S)-1-methyl-2-(4-


L4 ANSWER 8 OF 9 HCPLUS COPYRIGHT 2007 ACS on STN (Continued)
CN Morpholine, 4-[(2S)-2-[(3S)-3-[(6-chlorothieno[3,2-b]pyridin-2-yl)sulfonyl]amino]-2-oxo-1-pyrrolidinyl-1-oxopropyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 478644-76-7 HCPLUS

CN Morpholine, 4-[(2S)-2-[(3S)-3-[(1E)-2-(5-chloro-2-thienyl)ethyl]methylamino]-2-oxo-1-pyrrolidinyl-1-oxopropyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.


RN 478644-82-5 HCPLUS

CN Formic acid, compd. with 4-[(2S)-2-[(3S)-3-[(6-chloro-2-naphthalenylsulfonyl)2-(3-pyridylmethyl)amino]-2-oxo-1-pyrrolidinyl-1-oxopropyl]morpholine (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 478641-03-1
CMF C27 H29 Cl N4 O5 S

Absolute stereochemistry.



CM 2

CRN 64-18-6


10537646

L4 ANSWER 8 OF 9 HCPLUS COPYRIGHT 2007 ACS on STN (Continued)
CMF C H2 O2


O=CH-OH

RN 478825-55-7 HCPLUS
CN Glycine, N-[(6-chloro-2-naphthalenyl)sulfonyl]-N-[(2S)-1-[(1S)-2-[(2R,6S)-2,6-dimethyl-4-morpholinyl]-1-methyl-2-oxoethyl]-5-oxo-2-pyrrolidinyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

RN 478825-83-1 HCPLUS
CN Glycine, N-[(6-chlorobenzo[b]thien-2-yl)sulfonyl]-N-[(2S)-1-[(1S)-1-methyl-2-(4-morpholinyl)-2-oxoethyl]-5-oxo-2-pyrrolidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

RN 478825-85-3 HCPLUS
CN Glycine, N-[(5-chlorobenzo[b]thien-2-yl)sulfonyl]-N-[(2S)-1-[(1S)-1-methyl-2-(4-morpholinyl)-2-oxoethyl]-5-oxo-2-pyrrolidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




L4 ANSWER 9 OF 9 HCPLUS COPYRIGHT 2007 ACS on STN
 ED Entered STN: 24 Jul 1993
 ACCESSION NUMBER: 1993:428019 HCPLUS
 DOCUMENT NUMBER: 119:28019
 TITLE: Preparation and thrombin inhibition activity of 2-(arylsulfonamido)oxopiperidino-3-(4-aminophenyl)propionates and analogs
 INVENTOR(S): Mack, Helmut; Pfeiffer, Thomas; Hoeffken, Hans; Wolfgang Boehm, Hans Joachim; Horeberger, Wilfried
 PATENT ASSIGNEE(S): BASF A.-G., Germany
 SOURCE: Ger. Offen., 18 pp.
 CODEN: GWXKBX
 DOCUMENT TYPE: Patent
 LANGUAGE: German
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
DE 4121947	A1	19930107	DE 1991-4121947	19910703
CA 2112580	A1	19930121	CA 1992-2112580	19920623
WO 9301208	A1	19930121	WO 1992-EP1411	19920623
W: CA, JP, US H: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LU, MC, NL, SE JP 06509076 EP 668869 EP 668869				
T 19940103	JP 1992-501914	19920623		
A1 19950830	EP 1992-913125	19920623		
B1 19980513				
R: AT, BE, CH, DE, DK, ES, FR, GB, IT, LI, NL, SE AT 166065 ES 2115673 JP 3330600 US 5409583				
AT 19980515	AT 1992-913125	19920623		
T3 19980701	ES 1992-913125	19920623		
B2 20020930	JP 1993-501914	19920623		
A 19960206	US 1993-170357	19931228		
	DE 1991-4121947	A 19910703		
	WO 1992-EP1411	W 19920623		

OTHER SOURCE(S): MARPAT 119:28019

GI




AB The preparation of title compds. I (n = 1-5; A = amino, alkoxy; Ar = substituted Ph, α -, β -naphthyl) as thrombin inhibitors by standard procedures is claimed.
 IT 148134-65-0P
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (preparation and thrombin inhibition activity of)
 RN 148134-65-0 HCPLUS
 CN Morpholine, 4-[3-(4-(aminoiminomethyl)phenyl)-2-[3-[(6,7-dimethoxy-2-naphthalenyl)sulfonyl]amino]-2-oxo-1-pyrrolidinyl]-1-oxopropyl- (9CI) (CA INDEX NAME)

L4 ANSWER 9 OF 9 HCPLUS COPYRIGHT 2007 ACS on STN (Continued)

REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 9 OF 9 HCPLUS COPYRIGHT 2007 ACS on STN (Continued)



10537646

=> log y

COST IN U.S. DOLLARS

	SINCE FILE	TOTAL
	ENTRY	SESSION
	52.63	224.94

FULL ESTIMATED COST

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)

	SINCE FILE	TOTAL
	ENTRY	SESSION
	-7.02	-7.02

CA SUBSCRIBER PRICE

STN INTERNATIONAL LOGOFF AT 07:56:30 ON 28 MAR 2007